Arginase Deficiency

Mendelian MONDO:0008814 Pathograph 33 Urea Cycle Disorder Inborn Error of Metabolism

Arginase 1 (ARG1) deficiency is a rare autosomal recessive urea cycle disorder caused by biallelic pathogenic variants in the ARG1 gene. ARG1 catalyzes the final step of the urea cycle, hydrolyzing L-arginine to ornithine and urea. Loss of ARG1 activity leads to persistent hyperargininemia and accumulation of neurotoxic guanidino compounds, with relatively infrequent hyperammonemia compared to other urea cycle disorders. The hallmark clinical presentation includes progressive spastic diplegia or paraparesis, seizures, intellectual disability, and growth retardation, typically manifesting in early childhood. The estimated global birth prevalence is approximately 2.8 per 1,000,000 live births.

Ask OpenScientist

Ask a research question about Arginase Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
12
Phenotypes
33
Pathograph
1
Genes
8
Treatments
40
References
2
Deep Research
⚙

Pathophysiology

5
ARG1 molecular function deficiency
Biallelic pathogenic ARG1 variants reduce arginase catalytic activity in hepatocytes.
hepatocyte link
ARG1 link
arginase activity link
cytosol link
liver link
Downstream
Impaired ureagenesis and hyperargininemia Loss of ARG1 catalytic function reduces terminal urea-cycle flux and elevates arginine.
Erythrocyte arginase activity ARG1 loss produces reduced or absent arginase enzyme activity, including the erythrocyte assay used diagnostically.
Hepatomegaly Hepatic ARG1 deficiency can present with cholestatic liver disease and hepatosplenomegaly in neonatal cases.
Show evidence (1 reference)
PMID:26467175 SUPPORT Human Clinical
"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."
Supports ARG1 deficiency as the initiating molecular defect in arginase deficiency.
Impaired ureagenesis and hyperargininemia
Loss of ARG1 activity causes persistent hyperargininemia with plasma arginine levels exceeding 300 umol/L, impaired nitrogen disposal, and intermittent hyperammonemia during catabolic stress. Unlike other urea cycle disorders, hyperammonemia is relatively infrequent, and the dominant disease driver is chronic arginine toxicity.
urea cycle link arginine catabolic process link
Downstream
Hyperargininemia Loss of ARG1-mediated arginine hydrolysis causes marked plasma arginine elevation.
Plasma arginine ARG1 loss elevates plasma arginine, the primary biochemical monitoring analyte.
Urea Impaired terminal urea-cycle flux decreases conversion of arginine to urea.
Ornithine Impaired ARG1 hydrolysis decreases ornithine production from arginine.
Ammonia Impaired ureagenesis can produce intermittent ammonia elevation during catabolic stress.
Hyperammonemia ARG1-D causes infrequent but clinically relevant hyperammonemic episodes.
Encephalopathy In severe ARG1-D, intermittent hyperammonemia can progress to acute hyperammonemic coma, captured clinically as encephalopathy.
Growth retardation Persistent hyperargininemia in ARG1-D is associated with chronic growth failure in the core clinical syndrome.
Neurotoxicity from guanidino compound accumulation Chronic arginine, ammonia, and guanidino-compound accumulation acts as neurotoxic exposure.
Guanidino compounds ARG1-D causes accumulation of arginine metabolites, including guanidino compounds.
Arginine-nitric oxide pathway dysregulation Increased arginine availability can perturb arginine partitioning into nitric oxide and related pathways.
Show evidence (1 reference)
PMID:38292042 SUPPORT Human Clinical
"Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions in quality of life, and premature mortality."
Confirms hyperargininemia as the central biochemical feature of ARG1-D.
Neurotoxicity from guanidino compound accumulation
Accumulation of arginine and its downstream guanidino compound derivatives contributes to neurotoxicity through multiple mechanisms including inhibition of GABAergic and glycinergic neurotransmission, disruption of Na+/K+-ATPase activity, and induction of oxidative stress in brain tissue. These neurotoxic effects underlie the progressive neurological deterioration characteristic of the disease.
neuron link
response to oxidative stress link synaptic transmission, GABAergic link
brain link
Downstream
CNS white matter pathology Chronic metabolite neurotoxicity contributes to neuronal damage and downstream white matter pathology.
Spastic paraparesis Metabolite neurotoxicity underlies the progressive spastic paraparesis hallmark of ARG1-D.
Spasticity Progressive neurologic toxicity produces treatable pediatric spasticity.
Seizures Accumulated neurotoxic metabolites contribute to seizures in hyperargininemia.
Intellectual disability Chronic metabolite neurotoxicity contributes to progressive intellectual impairment.
Global developmental delay Chronic metabolite neurotoxicity contributes to developmental delay and cognitive impairment.
Microcephaly Progressive neurologic involvement in ARG1 deficiency can include microcephaly.
Show evidence (2 references)
PMID:26467175 PARTIAL Human Clinical
"This review briefly highlights the current understanding of the etiology and pathophysiology of ARG1 deficiency derived from clinical case reports and therapeutic strategies stretching over several decades and reports on several exciting new developments regarding the pathophysiology of the..."
Reviews pathophysiology of ARG1 deficiency but the abstract does not specifically detail guanidino compound neurotoxic mechanisms.
DOI:10.3390/app14041647 SUPPORT Human Clinical
"Different factors, such as the accumulation of arginine, ammonia, and guanidino compounds, act as neurotoxins and may account for the neurological sequelae observed in the disease."
Directly supports neurotoxicity from accumulated arginine-related metabolites.
CNS white matter pathology
White matter lesions, altered white-matter MRS patterns, and cortical or cerebellar atrophy are modeled as central nervous system substrates for progressive spasticity in ARG1 deficiency.
white matter link
Downstream
Abnormal cerebral white matter morphology White matter lesions and abnormal white-matter imaging are captured as abnormal cerebral white matter morphology.
Spastic paraparesis White matter and corticospinal tract pathology contributes to progressive spastic paraparesis.
Show evidence (2 references)
PMID:20456883 SUPPORT Human Clinical
"The magnetic resonance imaging (MRI) of our case showed severe multicystic white matter lesions with cortical atrophy"
Directly supports clinically observed white matter pathology in ARG1 deficiency.
PMID:22633632 SUPPORT Human Clinical
"Progressive spastic diplegia constituted the key clinical abnormality in this group, but variability in clinical presentation and progression were evident in our series."
Clinical evidence of progressive spasticity consistent with corticospinal tract and white matter pathology.
Arginine-nitric oxide pathway dysregulation
Arginine is a shared substrate for arginase and nitric oxide synthase (NOS). Loss of ARG1 activity shifts arginine partitioning and may perturb nitric oxide and polyamine biosynthesis, with implications for vascular function and cellular signaling. ARG1 is also expressed in erythrocytes and immune cells, suggesting broader metabolic consequences beyond the hepatic urea cycle.
erythrocyte link
nitric oxide biosynthetic process link
Show evidence (1 reference)
PMID:26467175 PARTIAL Human Clinical
"Finally, some of the functions and implications of ARG1 in non-urea cycle activities are considered."
Mentions non-urea cycle ARG1 activities but does not specifically detail NO pathway dysregulation in the abstract.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Arginase Deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

12
Digestive 1
Hepatomegaly Hepatomegaly (HP:0002240)
Hepatomegaly has been reported in case reports of ARG1 deficiency but robust frequency data are lacking.
Show evidence (1 reference)
PMID:21229317 SUPPORT Human Clinical
"In case 1, diagnosis was established at 2 months of age upon investigation of the etiology of cholestatic injury pattern and hepatosplenomegaly"
Supports hepatosplenomegaly as part of hepatic presentation in ARG1 deficiency.
Head and Neck 1
Microcephaly Microcephaly (HP:0000252)
Microcephaly has been reported in some ARG1-deficient patients but available abstracts do not quantify its frequency.
Show evidence (1 reference)
PMID:23920045 SUPPORT Other
"It usually presents with an insidious onset and manifests with a progressive neurological syndrome with microcephaly, spasticity, seizures, clonus, spastic diplegia, and failure to thrive"
The paper's background summarizes reported human clinical features of arginase deficiency and includes microcephaly.
Metabolism 2
Hyperammonemia OCCASIONAL Hyperammonemia (HP:0001987)
Sequelae: Encephalopathy
Show evidence (2 references)
PMID:26467175 SUPPORT Human Clinical
"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."
Describes hyperammonemia as infrequent but present during catabolic stress.
PMID:38292042 SUPPORT Human Clinical
"Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions in quality of life, and premature mortality."
Confirms that metabolite accumulation is part of the ARG1-D clinical spectrum.
Hyperargininemia VERY_FREQUENT Hyperargininemia (HP:0500153)
Sequelae: Growth retardation
Show evidence (2 references)
PMID:38292042 SUPPORT Human Clinical
"Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions in quality of life, and premature mortality."
Confirms marked increases in plasma arginine as the defining biochemical characteristic.
PMID:26467175 SUPPORT Human Clinical
"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."
Identifies hyperargininemia as the primary biochemical finding in ARG1 deficiency.
Musculoskeletal 2
Spastic paraparesis VERY_FREQUENT Spastic paraparesis (HP:0002313)
Show evidence (2 references)
PMID:26467175 SUPPORT Human Clinical
"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."
Identifies spastic paraparesis as a hallmark feature of ARG1 deficiency.
PMID:22633632 SUPPORT Human Clinical
"Progressive spastic diplegia constituted the key clinical abnormality in this group, but variability in clinical presentation and progression were evident in our series."
Confirms progressive spastic diplegia as the key clinical abnormality in a 16-patient cohort.
Spasticity VERY_FREQUENT Spasticity (HP:0001257)
Show evidence (1 reference)
PMID:22633632 SUPPORT Human Clinical
"Hyperargininemia is one of the few treatable causes of pediatric spastic paraparesis, and can be confused with cerebral palsy."
Identifies spasticity as a dominant feature frequently confused with cerebral palsy.
Nervous System 5
Seizures FREQUENT Seizure (HP:0001250)
Show evidence (2 references)
PMID:22633632 SUPPORT Human Clinical
"Seizures in hyperargininemia may be more common than reported in previous studies."
Directly supports that seizures are frequent and potentially underreported.
PMID:22633632 SUPPORT Human Clinical
"Hyperargininemia is an autosomal recessive metabolic disorder caused by a deficiency of enzyme arginase I. It is a rare pan-ethnic disease with a clinical presentation distinct from that of other urea cycle disorders, and hyperammonemic encephalopathy is not usually observed."
Confirms distinct clinical presentation where seizures, not hyperammonemic encephalopathy, dominate.
Intellectual disability FREQUENT Intellectual disability (HP:0001249)
Show evidence (1 reference)
PMID:26467175 SUPPORT Human Clinical
"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."
Directly identifies progressive intellectual impairment as a clinical feature of ARG1 deficiency.
Global developmental delay FREQUENT Global developmental delay (HP:0001263)
Developmental delay is commonly reported in hyperargininemia case series, though specific frequency data from published abstracts are limited.
Show evidence (1 reference)
DOI:10.3390/app14041647 SUPPORT Human Clinical
"The disease is associated with progressive development of spasticity and other symptoms, including seizures, developmental delay, cognitive impairment, and hepatic pathology."
Review-level evidence directly lists developmental delay among associated ARG1-D symptoms.
Encephalopathy OCCASIONAL Encephalopathy (HP:0001298)
Show evidence (2 references)
PMID:22633632 SUPPORT Human Clinical
"Hyperargininemia is an autosomal recessive metabolic disorder caused by a deficiency of enzyme arginase I. It is a rare pan-ethnic disease with a clinical presentation distinct from that of other urea cycle disorders, and hyperammonemic encephalopathy is not usually observed."
Confirms that hyperammonemic encephalopathy can occur but is not a usual finding.
PMID:41684183 SUPPORT Human Clinical
"The main clinical features at diagnosis included hyperammonemic coma (with or without liver failure) and neurodevelopmental delay with spastic diplegia."
Describes hyperammonemic coma at diagnosis in a severe ARG1-D cohort, supporting acute encephalopathy as a disease manifestation.
Abnormal cerebral white matter morphology Abnormal cerebral white matter morphology (HP:0002500)
Show evidence (2 references)
PMID:20456883 SUPPORT Human Clinical
"The magnetic resonance imaging (MRI) of our case showed severe multicystic white matter lesions with cortical atrophy"
Directly supports abnormal cerebral white matter morphology in ARG1 deficiency.
PMID:18321250 SUPPORT Human Clinical
"We observed mild cerebral and cerebellar atrophy and infarct at bilateral posterior putamen and insular cortex localization on conventional images and elevated choline/creatine ratios and abnormal peak at 3.8 ppm"
Supports cerebral and white-matter neuroimaging abnormalities in hyperargininemia.
Growth 1
Growth retardation VERY_FREQUENT Short stature (HP:0004322)
Show evidence (1 reference)
PMID:26467175 SUPPORT Human Clinical
"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."
Identifies persistent growth retardation as a characteristic feature of ARG1 deficiency.
🧬

Genetic Associations

1
ARG1 pathogenic variants
Autosomal recessive
Show evidence (2 references)
PMID:26467175 SUPPORT Human Clinical
"This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea."
Describes the genetic basis including mutation spectrum and functional consequences.
CGGV:assertion_0157f793-9232-4700-bbf0-dfb16270f688-2020-06-29T174101.533Z SUPPORT Other
"ARG1 | HGNC:663 | hyperargininemia | MONDO:0008814 | AR | Definitive"
ClinGen classifies the ARG1-hyperargininemia gene-disease relationship as definitive with autosomal recessive inheritance.
💊

Treatments

8
Protein-restricted diet
Action: dietary intervention MAXO:0000088
Dietary protein restriction with supplementation of essential amino acids is the cornerstone of chronic management. The primary goal is to reduce plasma arginine concentration below 200 umol/L, though this target is rarely achievable with diet alone due to endogenous arginine production.
Mechanism Target:
MODULATES Impaired ureagenesis and hyperargininemia — Protein restriction reduces arginine intake and nitrogen load, addressing the hyperargininemia mechanism.
Target Phenotypes: Hyperargininemia ↗
Nitrogen scavenger therapy
Action: nitrogen scavenger therapy Ontology label: Pharmacotherapy NCIT:C15986
Nitrogen scavengers including sodium benzoate, sodium phenylbutyrate, and sodium phenylacetate are used to provide alternative pathways for nitrogen excretion, particularly during hyperammonemic episodes and as chronic adjunctive therapy.
Target Phenotypes: Hyperammonemia ↗
Pegzilarginase enzyme replacement therapy
Action: Pharmacotherapy NCIT:C15986
Pegzilarginase is a pegylated recombinant human arginase 1 enzyme therapy that represents the first potential disease-modifying treatment for ARG1-D. In the Phase 3 PEACE trial, weekly pegzilarginase reduced geometric mean plasma arginine from 354 to 86 umol/L at 24 weeks, normalizing levels in 90.5% of patients compared to 0% with placebo, with clinically relevant functional mobility improvements.
Mechanism Target:
RESTORES Impaired ureagenesis and hyperargininemia — Pegzilarginase supplies arginase activity to normalize plasma arginine.
Show evidence (1 reference)
PMID:38292042 SUPPORT Human Clinical
"Pegzilarginase lowered geometric mean pArg from 354.0 μmol/L to 86.4 μmol/L at Week 24 vs 464.7 to 426.6 μmol/L for placebo"
Directly supports pegzilarginase correction of the hyperargininemia mechanism.
Target Phenotypes: Hyperargininemia ↗ Spastic paraparesis ↗
Show evidence (1 reference)
PMID:38292042 SUPPORT Human Clinical
"In addition, clinically relevant functional mobility improvements were demonstrated with pegzilarginase treatment. These effects were sustained long-term through additional 24 weeks of subsequent exposure."
Demonstrates sustained clinical mobility improvements beyond biochemical correction.
Liver transplantation
Action: liver transplantation MAXO:0001175
Liver transplantation can restore hepatic urea cycle function and halt neurological deterioration. It is considered for patients with severe metabolic instability refractory to medical management.
Mechanism Target:
RESTORES Impaired ureagenesis and hyperargininemia — Liver transplantation can restore hepatic urea-cycle function in severe urea-cycle disorders.
Antispasticity management
Action: supportive care MAXO:0000950
Symptomatic treatment of spasticity with physical therapy, botulinum toxin injections, and oral antispasticity agents to maintain mobility and prevent contractures. Early intervention is important given the progressive nature of the motor involvement.
Target Phenotypes: Spastic paraparesis ↗ Spasticity ↗
Show evidence (1 reference)
PMID:22633632 SUPPORT Human Clinical
"Hyperargininemia is one of the few treatable causes of pediatric spastic paraparesis, and can be confused with cerebral palsy."
Identifying the treatable nature of spasticity supports active spasticity management.
Antiepileptic therapy
Action: antiepileptic drug therapy Ontology label: anticonvulsant agent therapy MAXO:0000167
Seizure management with appropriate antiepileptic drugs, given that seizures occur in 60-75% of patients. Seizure control is an important aspect of supportive care.
Target Phenotypes: Seizure ↗
Show evidence (2 references)
PMID:22633632 SUPPORT Human Clinical
"Seizures in hyperargininemia may be more common than reported in previous studies."
High seizure frequency supports the need for antiepileptic management.
PMID:20301338 SUPPORT Other
"Agents/circumstances to avoid: Valproic acid (exacerbates hyperammonemia)."
GeneReviews identifies valproic acid as an agent to avoid because it can exacerbate hyperammonemia.
Newborn screening
Action: disease screening MAXO:0000124
Arginase deficiency is detectable by newborn screening using tandem mass spectrometry with elevated arginine as the primary marker. Use of the arginine-to-ornithine ratio improves sensitivity and specificity, as neonatal arginine levels may appear near-normal due to maternal arginase or ARG2 activity.
Target Phenotypes: Hyperargininemia ↗
Show evidence (1 reference)
PMID:28659245 SUPPORT Human Clinical
"Improved newborn screening effectiveness should lead to better case detection and more rapid treatment to lower plasma arginine levels hence improving long term outcome of individuals with hyperargininemia."
Supports early detection through newborn screening for improved outcomes.
Genetic counseling
Action: genetic counseling MAXO:0000079
Genetic counseling for affected families including discussion of autosomal recessive inheritance, 25% recurrence risk, carrier testing, and prenatal diagnostic options. Carrier screening implications are increasingly recognized given the expanding understanding of ARG1 variant pathogenicity.
Mechanism Target:
MODULATES ARG1 pathogenic variants — Counseling and reproductive testing are anchored to the family's ARG1 pathogenic variants.
Show evidence (1 reference)
PMID:20301338 SUPPORT Other
"Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the ARG1 pathogenic variants in the family are known."
GeneReviews supports carrier and prenatal testing when familial ARG1 variants are known.
Show evidence (2 references)
PMID:26467175 SUPPORT Human Clinical
"Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle, leading to impaired ureagenesis."
Autosomal recessive inheritance pattern supports the role of genetic counseling.
PMID:20301338 SUPPORT Other
"GENETIC COUNSELING: Arginase deficiency is inherited in an autosomal recessive manner."
GeneReviews directly supports genetic counseling for autosomal recessive inheritance.
🔬

Biochemical Markers

6
Plasma arginine (INCREASED)
Context: Markedly elevated plasma arginine is the hallmark biochemical abnormality, with levels often exceeding 300 umol/L (normal upper limit approximately 75 umol/L). The therapeutic target is to reduce plasma arginine below 200 umol/L. Arginine is the primary biomarker for diagnosis, monitoring, and therapeutic response assessment.
Pathograph Readouts
Readout Of Impaired ureagenesis and hyperargininemia Positive Diagnostic
Increased plasma arginine directly reports the terminal urea-cycle block and hyperargininemia mechanism in ARG1 deficiency.
Show evidence (1 reference)
PMID:38292042 SUPPORT Human Clinical
"Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites"
Phase 3 clinical trial evidence identifies plasma arginine elevation as the defining ARG1-D biochemical abnormality.
Pharmacodynamic Marker Of Impaired ureagenesis and hyperargininemia Negative Pharmacodynamic
Falling plasma arginine reports pharmacodynamic restoration of arginine disposal with pegzilarginase enzyme therapy.
Show evidence (1 reference)
PMID:38292042 SUPPORT Human Clinical
"Pegzilarginase lowered geometric mean pArg from 354.0 μmol/L to 86.4 μmol/L at Week 24 vs 464.7 to 426.6 μmol/L for placebo"
Trial evidence directly supports plasma arginine as a pharmacodynamic marker of pegzilarginase effect.
Show evidence (1 reference)
PMID:38292042 SUPPORT Human Clinical
"Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites"
Directly supports increased plasma arginine as the defining biochemical abnormality.
Guanidino compounds (INCREASED)
Context: Guanidino compounds including guanidinoacetate and alpha-keto-guanidinovalerate are elevated in blood, CSF, and brain tissue of ARG1-deficient patients. These neurotoxic metabolites are implicated in the progressive neurological deterioration through inhibition of GABAergic and glycinergic neurotransmission and induction of oxidative stress.
Pathograph Readouts
Readout Of Neurotoxicity from guanidino compound accumulation Positive Monitoring
Increased guanidino compounds report the neurotoxic metabolite branch downstream of chronic hyperargininemia.
Show evidence (1 reference)
DOI:10.3390/app14041647 SUPPORT Human Clinical
"Different factors, such as the accumulation of arginine, ammonia, and guanidino compounds, act as neurotoxins and may account for the neurological sequelae observed in the disease."
Review evidence links guanidino-compound accumulation to neurotoxicity and neurologic sequelae.
Show evidence (1 reference)
DOI:10.3390/app14041647 SUPPORT Human Clinical
"Different factors, such as the accumulation of arginine, ammonia, and guanidino compounds, act as neurotoxins and may account for the neurological sequelae observed in the disease."
Supports increased guanidino compounds and their neurotoxic role.
Ornithine (DECREASED)
Context: Reduced ornithine production results from impaired ARG1-mediated arginine hydrolysis. The arginine-to-ornithine ratio is a useful diagnostic discriminator in newborn screening, with a ratio of 1.4 or greater supporting identification of affected individuals.
Pathograph Readouts
Readout Of Impaired ureagenesis and hyperargininemia Negative Diagnostic
Decreased ornithine and an increased arginine-to-ornithine ratio report the impaired ARG1 hydrolysis reaction.
Show evidence (1 reference)
PMID:26467175 SUPPORT Human Clinical
"This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea."
Loss of ARG1-catalyzed hydrolysis directly supports decreased ornithine generation.
Predicts Impaired ureagenesis and hyperargininemia Negative Diagnostic
The arginine-to-ornithine ratio improves newborn-screening discrimination for hyperargininemia.
Show evidence (1 reference)
PMID:28659245 SUPPORT Human Clinical
"We also review other data that support improved screening efficacy by utilizing the arginine/ornithine ratio and other amino acid ratios as discriminators in the screening algorithm."
Newborn-screening evidence supports the arginine-to-ornithine ratio as a diagnostic discriminator.
Show evidence (1 reference)
PMID:26467175 SUPPORT Human Clinical
"This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea."
Loss of the ARG1 hydrolysis reaction supports decreased ornithine production.
Ammonia (INCREASED)
Context: Episodic hyperammonemia occurs during catabolic stress but is notably less frequent than in other urea cycle disorders. Ammonia elevations are typically moderate and intermittent rather than severe and persistent.
Pathograph Readouts
Readout Of Hyperammonemia Positive Monitoring
Increased ammonia reports intermittent hyperammonemic episodes in ARG1 deficiency, especially during catabolic stress.
Show evidence (1 reference)
PMID:26467175 SUPPORT Human Clinical
"infrequent episodes of hyperammonemia"
Review evidence supports hyperammonemia as an intermittent biochemical and clinical feature of ARG1-D.
Show evidence (1 reference)
PMID:26467175 SUPPORT Human Clinical
"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."
Describes hyperammonemia as infrequent but present in ARG1 deficiency.
Erythrocyte arginase activity (DECREASED)
Context: ARG1 activity measured in erythrocytes is reduced or absent in affected patients. Erythrocyte arginase assay serves as a functional confirmatory test alongside genetic testing and amino acid analysis.
Pathograph Readouts
Readout Of ARG1 molecular function deficiency Negative Diagnostic
Reduced erythrocyte arginase activity functionally reports the ARG1 molecular-function deficiency.
Show evidence (1 reference)
PMID:26467175 SUPPORT Human Clinical
"This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea."
Review evidence supports reduced or absent enzyme function as the direct molecular defect.
Show evidence (1 reference)
PMID:26467175 SUPPORT Human Clinical
"This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea."
Supports reduced or absent ARG1 enzyme activity as a diagnostic finding.
Urea (DECREASED)
Context: Urea production is reduced due to impaired ARG1-mediated conversion of arginine to urea and ornithine, reflecting the fundamental block in the final step of the urea cycle.
Pathograph Readouts
Readout Of Impaired ureagenesis and hyperargininemia Negative Diagnostic
Decreased urea production reports impaired terminal urea-cycle flux from loss of ARG1-catalyzed arginine hydrolysis.
Show evidence (1 reference)
PMID:26467175 SUPPORT Human Clinical
"Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle, leading to impaired ureagenesis."
Review evidence directly states impaired ureagenesis in ARG1 deficiency.
Show evidence (1 reference)
PMID:26467175 SUPPORT Human Clinical
"Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle, leading to impaired ureagenesis."
Directly states impaired ureagenesis as a consequence of ARG1 deficiency.
{ }

Source YAML

click to show 
name: Arginase Deficiency
category: Mendelian
creation_date: '2025-06-12T20:16:27Z'
updated_date: '2026-05-21T01:27:40Z'
synonyms:
- Argininemia
- Hyperargininemia
- ARG1 deficiency
- Arginase 1 deficiency
description: 'Arginase 1 (ARG1) deficiency is a rare autosomal recessive urea cycle disorder caused by biallelic pathogenic variants in the ARG1 gene. ARG1 catalyzes the final step of the urea cycle, hydrolyzing L-arginine to ornithine and urea. Loss of ARG1 activity leads to persistent hyperargininemia and accumulation of neurotoxic guanidino compounds, with relatively infrequent hyperammonemia compared to other urea cycle disorders. The hallmark clinical presentation includes progressive spastic diplegia or paraparesis, seizures, intellectual disability, and growth retardation, typically manifesting in early childhood. The estimated global birth prevalence is approximately 2.8 per 1,000,000 live births.

  '
disease_term:
  preferred_term: arginase deficiency
  term:
    id: MONDO:0008814
    label: arginase deficiency
parents:
- Urea Cycle Disorder
- Inborn Error of Metabolism
prevalence:
- population: Global
  notes: 'Estimated global birth prevalence is approximately 2.8 cases per 1,000,000 live births, with a population prevalence of approximately 1.4 cases per 1,000,000 people.

    '
  evidence:
  - reference: PMID:39669610
    reference_title: "ACMG/AMP variant classification framework in arginase 1 deficiency: Implications for birth prevalence estimates and diagnostics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Mutant allele frequency estimates ranged from 17 to 266 per 100,000 and birth prevalence from 1 in 141,331 to 34,602,076.
    explanation: Provides birth prevalence range estimates based on allele frequency analysis.
progression:
- phase: Neonatal biochemical phase
  notes: 'Persistent hyperargininemia develops in infancy. Newborn screening may miss cases because plasma arginine levels may appear normal or near-normal due to maternal arginase or ARG2 activity. Arginine-to-ornithine ratio improves detection sensitivity.

    '
- phase: Progressive neurological deterioration
  age_range: Early childhood through adolescence
  notes: 'Progressive spastic diplegia or paraparesis typically emerges in early childhood, with seizures and cognitive decline following. Accumulation of guanidino compounds drives neurotoxicity. Late disease features include cerebral and cerebellar atrophy, corticospinal tract degeneration, and progressive mobility impairment.

    '
  evidence:
  - reference: PMID:22633632
    reference_title: "Clinical features and neurologic progression of hyperargininemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Progressive spastic diplegia constituted the key clinical abnormality in this group, but variability in clinical presentation and progression were evident in our series.
    explanation: Describes the progressive neurological course with variability.
pathophysiology:
- name: ARG1 molecular function deficiency
  description: 'Biallelic pathogenic ARG1 variants reduce arginase catalytic activity in hepatocytes.

    '
  genes:
  - preferred_term: ARG1
    term:
      id: hgnc:663
      label: ARG1
  molecular_functions:
  - preferred_term: arginase activity
    term:
      id: GO:0004053
      label: arginase activity
  cellular_components:
  - preferred_term: cytosol
    term:
      id: GO:0005829
      label: cytosol
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders.
    explanation: Supports ARG1 deficiency as the initiating molecular defect in arginase deficiency.
  downstream:
  - target: Impaired ureagenesis and hyperargininemia
    description: Loss of ARG1 catalytic function reduces terminal urea-cycle flux and elevates arginine.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea.
      explanation: Directly supports the causal edge from ARG1 loss of enzyme function to impaired terminal urea-cycle flux.
  - target: Erythrocyte arginase activity
    description: ARG1 loss produces reduced or absent arginase enzyme activity, including the erythrocyte assay used diagnostically.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea.
      explanation: Supports decreased arginase activity as a direct consequence of ARG1 pathogenic variants.
  - target: Hepatomegaly
    description: Hepatic ARG1 deficiency can present with cholestatic liver disease and hepatosplenomegaly in neonatal cases.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cholestatic liver disease
    - hepatic dysfunction
    evidence:
    - reference: PMID:21229317
      reference_title: "Neonatal cholestasis: an uncommon presentation of hyperargininemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: In case 1, diagnosis was established at 2 months of age upon investigation of the etiology of cholestatic injury pattern and hepatosplenomegaly
      explanation: Supports hepatic involvement with hepatosplenomegaly as a manifestation of ARG1 deficiency.
- name: Impaired ureagenesis and hyperargininemia
  description: 'Loss of ARG1 activity causes persistent hyperargininemia with plasma arginine levels exceeding 300 umol/L, impaired nitrogen disposal, and intermittent hyperammonemia during catabolic stress. Unlike other urea cycle disorders, hyperammonemia is relatively infrequent, and the dominant disease driver is chronic arginine toxicity.

    '
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  - preferred_term: arginine catabolic process
    term:
      id: GO:0006527
      label: L-arginine catabolic process
  chemical_entities:
  - preferred_term: L-arginine
    term:
      id: CHEBI:32682
      label: L-argininium(1+)
    modifier: INCREASED
  - preferred_term: urea
    term:
      id: CHEBI:16199
      label: urea
    modifier: DECREASED
  - preferred_term: L-ornithine
    term:
      id: CHEBI:46911
      label: L-ornithinium(1+)
    modifier: DECREASED
  - preferred_term: ammonia
    term:
      id: CHEBI:16134
      label: ammonia
    modifier: INCREASED
  - preferred_term: guanidinoacetate
    term:
      id: CHEBI:131444
      label: guanidinoacetate
    modifier: INCREASED
  evidence:
  - reference: PMID:38292042
    reference_title: "Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions in quality of life, and premature mortality.
    explanation: Confirms hyperargininemia as the central biochemical feature of ARG1-D.
  downstream:
  - target: Hyperargininemia
    description: Loss of ARG1-mediated arginine hydrolysis causes marked plasma arginine elevation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38292042
      reference_title: "Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites
      explanation: Directly links ARG1-D to marked plasma arginine elevation.
  - target: Plasma arginine
    description: ARG1 loss elevates plasma arginine, the primary biochemical monitoring analyte.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38292042
      reference_title: "Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites
      explanation: Supports the plasma arginine biochemical node as a direct consequence of impaired ARG1 function.
  - target: Urea
    description: Impaired terminal urea-cycle flux decreases conversion of arginine to urea.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea.
      explanation: Directly supports decreased urea production from loss of ARG1-catalyzed hydrolysis.
  - target: Ornithine
    description: Impaired ARG1 hydrolysis decreases ornithine production from arginine.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea.
      explanation: Directly supports decreased ornithine generation from the blocked ARG1 reaction.
  - target: Ammonia
    description: Impaired ureagenesis can produce intermittent ammonia elevation during catabolic stress.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired nitrogen disposal
    - catabolic stress
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: infrequent episodes of hyperammonemia
      explanation: Supports ammonia elevation as an intermittent downstream effect in ARG1 deficiency.
  - target: Hyperammonemia
    description: ARG1-D causes infrequent but clinically relevant hyperammonemic episodes.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired ureagenesis
    - catabolic stress
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: infrequent episodes of hyperammonemia
      explanation: Supports hyperammonemia as a downstream phenotype, while preserving its lower frequency in ARG1-D.
  - target: Encephalopathy
    description: In severe ARG1-D, intermittent hyperammonemia can progress to acute hyperammonemic coma, captured clinically as encephalopathy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired ureagenesis
    - hyperammonemia
    - hyperammonemic coma
    evidence:
    - reference: PMID:41684183
      reference_title: "Cluster of Severe Arginase 1 Deficiency in the Comoros: Clinical, Neuroimaging, and Molecular Features in 17 Patients From Mayotte Compared With 10 From Paris."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The main clinical features at diagnosis included hyperammonemic coma (with or without liver failure) and neurodevelopmental delay with spastic diplegia.
      explanation: Severe human ARG1-D cohort evidence supports acute hyperammonemic coma as a downstream manifestation of impaired nitrogen disposal.
  - target: Growth retardation
    description: Persistent hyperargininemia in ARG1-D is associated with chronic growth failure in the core clinical syndrome.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia
      explanation: Review of human ARG1-deficient patients links hyperargininemia with persistent growth retardation as part of the characteristic clinical pattern.
  - target: Neurotoxicity from guanidino compound accumulation
    description: Chronic arginine, ammonia, and guanidino-compound accumulation acts as neurotoxic exposure.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - accumulated arginine metabolites
    - guanidino compound toxicity
    evidence:
    - reference: DOI:10.3390/app14041647
      reference_title: "Argininemia: Pathophysiology and Novel Methods for Evaluation of the Disease"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Different factors, such as the accumulation of arginine, ammonia, and guanidino compounds, act as neurotoxins and may account for the neurological sequelae observed in the disease.
      explanation: Supports the metabolite-to-neurotoxicity edge in argininemia.
  - target: Guanidino compounds
    description: ARG1-D causes accumulation of arginine metabolites, including guanidino compounds.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.3390/app14041647
      reference_title: "Argininemia: Pathophysiology and Novel Methods for Evaluation of the Disease"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Different factors, such as the accumulation of arginine, ammonia, and guanidino compounds, act as neurotoxins and may account for the neurological sequelae observed in the disease.
      explanation: Supports guanidino-compound accumulation as a biochemical consequence of ARG1-D.
  - target: Arginine-nitric oxide pathway dysregulation
    description: Increased arginine availability can perturb arginine partitioning into nitric oxide and related pathways.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Neurotoxicity from guanidino compound accumulation
  description: 'Accumulation of arginine and its downstream guanidino compound derivatives contributes to neurotoxicity through multiple mechanisms including inhibition of GABAergic and glycinergic neurotransmission, disruption of Na+/K+-ATPase activity, and induction of oxidative stress in brain tissue. These neurotoxic effects underlie the progressive neurological deterioration characteristic of the disease.

    '
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: synaptic transmission, GABAergic
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
  chemical_entities:
  - preferred_term: guanidinoacetate
    term:
      id: CHEBI:131444
      label: guanidinoacetate
    modifier: INCREASED
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: This review briefly highlights the current understanding of the etiology and pathophysiology of ARG1 deficiency derived from clinical case reports and therapeutic strategies stretching over several decades and reports on several exciting new developments regarding the pathophysiology of the disorder using ARG1 global and inducible knockout mouse models.
    explanation: Reviews pathophysiology of ARG1 deficiency but the abstract does not specifically detail guanidino compound neurotoxic mechanisms.
  - reference: DOI:10.3390/app14041647
    reference_title: "Argininemia: Pathophysiology and Novel Methods for Evaluation of the Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Different factors, such as the accumulation of arginine, ammonia, and guanidino compounds, act as neurotoxins and may account for the neurological sequelae observed in the disease.
    explanation: Directly supports neurotoxicity from accumulated arginine-related metabolites.
  downstream:
  - target: CNS white matter pathology
    description: Chronic metabolite neurotoxicity contributes to neuronal damage and downstream white matter pathology.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic neurotoxic metabolite exposure
    - neuronal damage
    evidence:
    - reference: PMID:18321250
      reference_title: "Neuroimaging findings in hyperargininemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Though the pathogenesis of neuronal damage in hyperargininemia is not clear, high serum and cerebrospinal fluid arginine levels can be directly related with neuronal damage.
      explanation: Supports a metabolite-neurotoxicity link from elevated arginine to CNS injury.
  - target: Spastic paraparesis
    description: Metabolite neurotoxicity underlies the progressive spastic paraparesis hallmark of ARG1-D.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - progressive corticospinal motor pathway involvement
    evidence:
    - reference: PMID:22633632
      reference_title: "Clinical features and neurologic progression of hyperargininemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Progressive spastic diplegia constituted the key clinical abnormality in this group
      explanation: Connects progressive ARG1-D neurologic injury to the hallmark spastic paraparesis phenotype.
  - target: Spasticity
    description: Progressive neurologic toxicity produces treatable pediatric spasticity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - progressive spastic diplegia
    evidence:
    - reference: PMID:22633632
      reference_title: "Clinical features and neurologic progression of hyperargininemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hyperargininemia is one of the few treatable causes of pediatric spastic paraparesis
      explanation: Supports spasticity as a clinical consequence of hyperargininemia.
  - target: Seizures
    description: Accumulated neurotoxic metabolites contribute to seizures in hyperargininemia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - guanidino compound neurotoxicity
    - altered inhibitory neurotransmission
    evidence:
    - reference: PMID:22633632
      reference_title: "Clinical features and neurologic progression of hyperargininemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Seizures in hyperargininemia may be more common than reported in previous studies.
      explanation: Supports seizures as a frequent downstream neurologic manifestation.
  - target: Intellectual disability
    description: Chronic metabolite neurotoxicity contributes to progressive intellectual impairment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic neurotoxic metabolite exposure
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: progressive neurological and intellectual impairment
      explanation: Supports intellectual impairment as part of the downstream neurotoxicity phenotype.
  - target: Global developmental delay
    description: Chronic metabolite neurotoxicity contributes to developmental delay and cognitive impairment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic neurotoxic metabolite exposure
    evidence:
    - reference: DOI:10.3390/app14041647
      reference_title: "Argininemia: Pathophysiology and Novel Methods for Evaluation of the Disease"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The disease is associated with progressive development of spasticity and other symptoms, including seizures, developmental delay, cognitive impairment, and hepatic pathology.
      explanation: Supports developmental delay and cognitive impairment as part of the downstream neurological phenotype.
  - target: Microcephaly
    description: Progressive neurologic involvement in ARG1 deficiency can include microcephaly.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23920045
      reference_title: "Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: It usually presents with an insidious onset and manifests with a progressive neurological syndrome with microcephaly, spasticity, seizures, clonus, spastic diplegia, and failure to thrive
      explanation: The paper's background summarizes reported human clinical features, supporting microcephaly as part of the neurologic syndrome but not defining the exact causal intermediate.
- name: CNS white matter pathology
  description: 'White matter lesions, altered white-matter MRS patterns, and cortical or cerebellar atrophy are modeled as central nervous system substrates for progressive spasticity in ARG1 deficiency.

    '
  locations:
  - preferred_term: white matter
    term:
      id: UBERON:0002316
      label: white matter
  evidence:
  - reference: PMID:20456883
    reference_title: "A long-term survival case of arginase deficiency with severe multicystic white matter and compound mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The magnetic resonance imaging (MRI) of our case showed severe multicystic white matter lesions with cortical atrophy
    explanation: Directly supports clinically observed white matter pathology in ARG1 deficiency.
  - reference: PMID:22633632
    reference_title: "Clinical features and neurologic progression of hyperargininemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Progressive spastic diplegia constituted the key clinical abnormality in this group, but variability in clinical presentation and progression were evident in our series.
    explanation: Clinical evidence of progressive spasticity consistent with corticospinal tract and white matter pathology.
  downstream:
  - target: Abnormal cerebral white matter morphology
    description: White matter lesions and abnormal white-matter imaging are captured as abnormal cerebral white matter morphology.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20456883
      reference_title: "A long-term survival case of arginase deficiency with severe multicystic white matter and compound mutations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The magnetic resonance imaging (MRI) of our case showed severe multicystic white matter lesions with cortical atrophy
      explanation: Directly connects the white matter pathology mechanism to the neuroimaging phenotype node.
  - target: Spastic paraparesis
    description: White matter and corticospinal tract pathology contributes to progressive spastic paraparesis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract involvement
    evidence:
    - reference: PMID:22633632
      reference_title: "Clinical features and neurologic progression of hyperargininemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Progressive spastic diplegia constituted the key clinical abnormality in this group
      explanation: Supports progressive spastic diplegia as the clinical expression of the neurologic pathology.
- name: Arginine-nitric oxide pathway dysregulation
  description: 'Arginine is a shared substrate for arginase and nitric oxide synthase (NOS). Loss of ARG1 activity shifts arginine partitioning and may perturb nitric oxide and polyamine biosynthesis, with implications for vascular function and cellular signaling. ARG1 is also expressed in erythrocytes and immune cells, suggesting broader metabolic consequences beyond the hepatic urea cycle.

    '
  biological_processes:
  - preferred_term: nitric oxide biosynthetic process
    term:
      id: GO:0006809
      label: nitric oxide biosynthetic process
  cell_types:
  - preferred_term: erythrocyte
    term:
      id: CL:0000232
      label: erythrocyte
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Finally, some of the functions and implications of ARG1 in non-urea cycle activities are considered.
    explanation: Mentions non-urea cycle ARG1 activities but does not specifically detail NO pathway dysregulation in the abstract.
phenotypes:
- name: Spastic paraparesis
  frequency: VERY_FREQUENT
  description: 'Progressive spastic diplegia or paraparesis is the hallmark neurological feature, typically presenting in early childhood. Upper motor neuron involvement occurs in approximately 80% of patients, often initially mistaken for cerebral palsy.

    '
  phenotype_term:
    preferred_term: Spastic paraparesis
    term:
      id: HP:0002313
      label: Spastic paraparesis
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders.
    explanation: Identifies spastic paraparesis as a hallmark feature of ARG1 deficiency.
  - reference: PMID:22633632
    reference_title: "Clinical features and neurologic progression of hyperargininemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Progressive spastic diplegia constituted the key clinical abnormality in this group, but variability in clinical presentation and progression were evident in our series.
    explanation: Confirms progressive spastic diplegia as the key clinical abnormality in a 16-patient cohort.
- name: Hyperammonemia
  frequency: OCCASIONAL
  description: 'Episodic hyperammonemia occurs during catabolic stress, but is notably less frequent than in other urea cycle disorders. This distinguishing feature reflects the unique position of ARG1 as the terminal urea cycle enzyme with partial compensatory activity from ARG2.

    '
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders.
    explanation: Describes hyperammonemia as infrequent but present during catabolic stress.
  - reference: PMID:38292042
    reference_title: "Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions in quality of life, and premature mortality.
    explanation: Confirms that metabolite accumulation is part of the ARG1-D clinical spectrum.
  sequelae:
  - target: Encephalopathy
    description: Hyperammonemic crises can present with acute encephalopathy or coma.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41684183
      reference_title: "Cluster of Severe Arginase 1 Deficiency in the Comoros: Clinical, Neuroimaging, and Molecular Features in 17 Patients From Mayotte Compared With 10 From Paris."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The main clinical features at diagnosis included hyperammonemic coma (with or without liver failure) and neurodevelopmental delay with spastic diplegia.
      explanation: Supports hyperammonemic coma as a severe acute neurologic manifestation downstream of hyperammonemia.
- name: Seizures
  frequency: FREQUENT
  description: 'Seizures occur in approximately 60-75% of patients and are linked to the epileptogenic properties of accumulated guanidino compounds. Seizure frequency may be more common than historically reported.

    '
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:22633632
    reference_title: "Clinical features and neurologic progression of hyperargininemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seizures in hyperargininemia may be more common than reported in previous studies.
    explanation: Directly supports that seizures are frequent and potentially underreported.
  - reference: PMID:22633632
    reference_title: "Clinical features and neurologic progression of hyperargininemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperargininemia is an autosomal recessive metabolic disorder caused by a deficiency of enzyme arginase I. It is a rare pan-ethnic disease with a clinical presentation distinct from that of other urea cycle disorders, and hyperammonemic encephalopathy is not usually observed.
    explanation: Confirms distinct clinical presentation where seizures, not hyperammonemic encephalopathy, dominate.
- name: Intellectual disability
  frequency: FREQUENT
  description: 'Progressive intellectual impairment is a common feature, often developing in early childhood alongside motor deterioration. The cognitive decline is attributed to chronic neurotoxicity from accumulated arginine and guanidino compounds.

    '
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders.
    explanation: Directly identifies progressive intellectual impairment as a clinical feature of ARG1 deficiency.
- name: Global developmental delay
  frequency: FREQUENT
  description: 'Developmental delay is common, often preceding the recognition of spastic paraparesis and intellectual disability. Motor milestones may be delayed or lost as the disease progresses.

    '
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  notes: Developmental delay is commonly reported in hyperargininemia case series, though specific frequency data from published abstracts are limited.
  evidence:
  - reference: DOI:10.3390/app14041647
    reference_title: "Argininemia: Pathophysiology and Novel Methods for Evaluation of the Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The disease is associated with progressive development of spasticity and other symptoms, including seizures, developmental delay, cognitive impairment, and hepatic pathology.
    explanation: Review-level evidence directly lists developmental delay among associated ARG1-D symptoms.
- name: Growth retardation
  frequency: VERY_FREQUENT
  description: 'Persistent growth retardation is a characteristic feature, likely reflecting chronic catabolic stress and dietary protein restriction. Short stature is observed in the majority of patients.

    '
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders.
    explanation: Identifies persistent growth retardation as a characteristic feature of ARG1 deficiency.
- name: Spasticity
  frequency: VERY_FREQUENT
  description: 'Upper and lower extremity spasticity is a predominant motor finding, with corticospinal tract involvement. This is the feature most often leading to initial clinical evaluation and may be mistaken for cerebral palsy.

    '
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:22633632
    reference_title: "Clinical features and neurologic progression of hyperargininemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperargininemia is one of the few treatable causes of pediatric spastic paraparesis, and can be confused with cerebral palsy.
    explanation: Identifies spasticity as a dominant feature frequently confused with cerebral palsy.
- name: Encephalopathy
  frequency: OCCASIONAL
  description: 'Acute or recurrent encephalopathy may occur during hyperammonemic crises triggered by catabolic stress, though this is less common than in other urea cycle disorders.

    '
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:22633632
    reference_title: "Clinical features and neurologic progression of hyperargininemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperargininemia is an autosomal recessive metabolic disorder caused by a deficiency of enzyme arginase I. It is a rare pan-ethnic disease with a clinical presentation distinct from that of other urea cycle disorders, and hyperammonemic encephalopathy is not usually observed.
    explanation: Confirms that hyperammonemic encephalopathy can occur but is not a usual finding.
  - reference: PMID:41684183
    reference_title: "Cluster of Severe Arginase 1 Deficiency in the Comoros: Clinical, Neuroimaging, and Molecular Features in 17 Patients From Mayotte Compared With 10 From Paris."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The main clinical features at diagnosis included hyperammonemic coma (with or without liver failure) and neurodevelopmental delay with spastic diplegia.
    explanation: Describes hyperammonemic coma at diagnosis in a severe ARG1-D cohort, supporting acute encephalopathy as a disease manifestation.
- name: Hepatomegaly
  description: 'Hepatic involvement including hepatomegaly or hepatosplenomegaly may occur, particularly in rare neonatal cholestatic presentations of ARG1 deficiency.

    '
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  notes: Hepatomegaly has been reported in case reports of ARG1 deficiency but robust frequency data are lacking.
  evidence:
  - reference: PMID:21229317
    reference_title: "Neonatal cholestasis: an uncommon presentation of hyperargininemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In case 1, diagnosis was established at 2 months of age upon investigation of the etiology of cholestatic injury pattern and hepatosplenomegaly
    explanation: Supports hepatosplenomegaly as part of hepatic presentation in ARG1 deficiency.
- name: Hyperargininemia
  frequency: VERY_FREQUENT
  description: 'Persistent elevation of plasma arginine, often exceeding 300 umol/L, is the defining biochemical feature. Plasma arginine levels are the primary biomarker for disease monitoring and therapeutic response.

    '
  phenotype_term:
    preferred_term: Hyperargininemia
    term:
      id: HP:0500153
      label: Hyperargininemia
  evidence:
  - reference: PMID:38292042
    reference_title: "Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions in quality of life, and premature mortality.
    explanation: Confirms marked increases in plasma arginine as the defining biochemical characteristic.
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders.
    explanation: Identifies hyperargininemia as the primary biochemical finding in ARG1 deficiency.
  sequelae:
  - target: Growth retardation
    description: ARG1-deficient patients with hyperargininemia exhibit persistent growth retardation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia
      explanation: Supports growth retardation as part of the hyperargininemia clinical syndrome.
- name: Abnormal cerebral white matter morphology
  description: 'Neuroimaging abnormalities including white matter lesions, altered white-matter MRS metabolite patterns, cerebral atrophy, and cerebellar atrophy have been reported in hyperargininemia.

    '
  phenotype_term:
    preferred_term: Abnormal cerebral white matter morphology
    term:
      id: HP:0002500
      label: Abnormal cerebral white matter morphology
  evidence:
  - reference: PMID:20456883
    reference_title: "A long-term survival case of arginase deficiency with severe multicystic white matter and compound mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The magnetic resonance imaging (MRI) of our case showed severe multicystic white matter lesions with cortical atrophy
    explanation: Directly supports abnormal cerebral white matter morphology in ARG1 deficiency.
  - reference: PMID:18321250
    reference_title: "Neuroimaging findings in hyperargininemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We observed mild cerebral and cerebellar atrophy and infarct at bilateral posterior putamen and insular cortex localization on conventional images and elevated choline/creatine ratios and abnormal peak at 3.8 ppm
    explanation: Supports cerebral and white-matter neuroimaging abnormalities in hyperargininemia.
- name: Microcephaly
  description: 'Microcephaly has been reported as part of the progressive neurological syndrome in some patients with ARG1 deficiency; the precise causal intermediate is uncertain.

    '
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  notes: Microcephaly has been reported in some ARG1-deficient patients but available abstracts do not quantify its frequency.
  evidence:
  - reference: PMID:23920045
    reference_title: "Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: It usually presents with an insidious onset and manifests with a progressive neurological syndrome with microcephaly, spasticity, seizures, clonus, spastic diplegia, and failure to thrive
    explanation: The paper's background summarizes reported human clinical features of arginase deficiency and includes microcephaly.
biochemical:
- name: Plasma arginine
  presence: INCREASED
  context: 'Markedly elevated plasma arginine is the hallmark biochemical abnormality, with levels often exceeding 300 umol/L (normal upper limit approximately 75 umol/L). The therapeutic target is to reduce plasma arginine below 200 umol/L. Arginine is the primary biomarker for diagnosis, monitoring, and therapeutic response assessment.

    '
  biomarker_term:
    preferred_term: L-arginine
    term:
      id: CHEBI:32682
      label: L-argininium(1+)
  readouts:
  - target: Impaired ureagenesis and hyperargininemia
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Increased plasma arginine directly reports the terminal urea-cycle block
      and hyperargininemia mechanism in ARG1 deficiency.
    evidence:
    - reference: PMID:38292042
      reference_title: "Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites
      explanation: Phase 3 clinical trial evidence identifies plasma arginine elevation as the defining ARG1-D biochemical abnormality.
  - target: Impaired ureagenesis and hyperargininemia
    relationship: PHARMACODYNAMIC_MARKER_OF
    direction: NEGATIVE
    endpoint_context: PHARMACODYNAMIC
    interpretation: >-
      Falling plasma arginine reports pharmacodynamic restoration of arginine
      disposal with pegzilarginase enzyme therapy.
    evidence:
    - reference: PMID:38292042
      reference_title: "Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Pegzilarginase lowered geometric mean pArg from 354.0 μmol/L to 86.4 μmol/L at Week 24 vs 464.7 to 426.6 μmol/L for placebo
      explanation: Trial evidence directly supports plasma arginine as a pharmacodynamic marker of pegzilarginase effect.
  evidence:
  - reference: PMID:38292042
    reference_title: "Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites
    explanation: Directly supports increased plasma arginine as the defining biochemical abnormality.
- name: Guanidino compounds
  presence: INCREASED
  context: 'Guanidino compounds including guanidinoacetate and alpha-keto-guanidinovalerate are elevated in blood, CSF, and brain tissue of ARG1-deficient patients. These neurotoxic metabolites are implicated in the progressive neurological deterioration through inhibition of GABAergic and glycinergic neurotransmission and induction of oxidative stress.

    '
  biomarker_term:
    preferred_term: guanidinoacetate
    term:
      id: CHEBI:131444
      label: guanidinoacetate
  readouts:
  - target: Neurotoxicity from guanidino compound accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >-
      Increased guanidino compounds report the neurotoxic metabolite branch
      downstream of chronic hyperargininemia.
    evidence:
    - reference: DOI:10.3390/app14041647
      reference_title: "Argininemia: Pathophysiology and Novel Methods for Evaluation of the Disease"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Different factors, such as the accumulation of arginine, ammonia, and guanidino compounds, act as neurotoxins and may account for the neurological sequelae observed in the disease.
      explanation: Review evidence links guanidino-compound accumulation to neurotoxicity and neurologic sequelae.
  evidence:
  - reference: DOI:10.3390/app14041647
    reference_title: "Argininemia: Pathophysiology and Novel Methods for Evaluation of the Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Different factors, such as the accumulation of arginine, ammonia, and guanidino compounds, act as neurotoxins and may account for the neurological sequelae observed in the disease.
    explanation: Supports increased guanidino compounds and their neurotoxic role.
- name: Ornithine
  presence: DECREASED
  context: 'Reduced ornithine production results from impaired ARG1-mediated arginine hydrolysis. The arginine-to-ornithine ratio is a useful diagnostic discriminator in newborn screening, with a ratio of 1.4 or greater supporting identification of affected individuals.

    '
  biomarker_term:
    preferred_term: L-ornithine
    term:
      id: CHEBI:46911
      label: L-ornithinium(1+)
  readouts:
  - target: Impaired ureagenesis and hyperargininemia
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Decreased ornithine and an increased arginine-to-ornithine ratio report
      the impaired ARG1 hydrolysis reaction.
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea.
      explanation: Loss of ARG1-catalyzed hydrolysis directly supports decreased ornithine generation.
  - target: Impaired ureagenesis and hyperargininemia
    relationship: PREDICTS
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      The arginine-to-ornithine ratio improves newborn-screening discrimination
      for hyperargininemia.
    evidence:
    - reference: PMID:28659245
      reference_title: "Newborn screening for hyperargininemia due to arginase 1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: We also review other data that support improved screening efficacy by utilizing the arginine/ornithine ratio and other amino acid ratios as discriminators in the screening algorithm.
      explanation: Newborn-screening evidence supports the arginine-to-ornithine ratio as a diagnostic discriminator.
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea.
    explanation: Loss of the ARG1 hydrolysis reaction supports decreased ornithine production.
- name: Ammonia
  presence: INCREASED
  context: 'Episodic hyperammonemia occurs during catabolic stress but is notably less frequent than in other urea cycle disorders. Ammonia elevations are typically moderate and intermittent rather than severe and persistent.

    '
  biomarker_term:
    preferred_term: ammonia
    term:
      id: CHEBI:16134
      label: ammonia
  readouts:
  - target: Hyperammonemia
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >-
      Increased ammonia reports intermittent hyperammonemic episodes in ARG1
      deficiency, especially during catabolic stress.
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: infrequent episodes of hyperammonemia
      explanation: Review evidence supports hyperammonemia as an intermittent biochemical and clinical feature of ARG1-D.
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders.
    explanation: Describes hyperammonemia as infrequent but present in ARG1 deficiency.
- name: Erythrocyte arginase activity
  presence: DECREASED
  context: 'ARG1 activity measured in erythrocytes is reduced or absent in affected patients. Erythrocyte arginase assay serves as a functional confirmatory test alongside genetic testing and amino acid analysis.

    '
  biomarker_term:
    preferred_term: arginase-1
    term:
      id: NCIT:C103929
      label: Arginase-1
  readouts:
  - target: ARG1 molecular function deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Reduced erythrocyte arginase activity functionally reports the ARG1
      molecular-function deficiency.
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea.
      explanation: Review evidence supports reduced or absent enzyme function as the direct molecular defect.
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea.
    explanation: Supports reduced or absent ARG1 enzyme activity as a diagnostic finding.
- name: Urea
  presence: DECREASED
  context: 'Urea production is reduced due to impaired ARG1-mediated conversion of arginine to urea and ornithine, reflecting the fundamental block in the final step of the urea cycle.

    '
  biomarker_term:
    preferred_term: urea
    term:
      id: CHEBI:16199
      label: urea
  readouts:
  - target: Impaired ureagenesis and hyperargininemia
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Decreased urea production reports impaired terminal urea-cycle flux from
      loss of ARG1-catalyzed arginine hydrolysis.
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle, leading to impaired ureagenesis.
      explanation: Review evidence directly states impaired ureagenesis in ARG1 deficiency.
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle, leading to impaired ureagenesis.
    explanation: Directly states impaired ureagenesis as a consequence of ARG1 deficiency.
genetic:
- name: ARG1 pathogenic variants
  gene_term:
    preferred_term: ARG1
    term:
      id: hgnc:663
      label: ARG1
  inheritance:
  - name: Autosomal recessive
    description: 'Arginase 1 deficiency follows autosomal recessive inheritance. Both parents are obligate carriers with a 25% recurrence risk for each pregnancy.

      '
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle, leading to impaired ureagenesis.
      explanation: Directly identifies autosomal recessive inheritance.
    - reference: PMID:22633632
      reference_title: "Clinical features and neurologic progression of hyperargininemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hyperargininemia is an autosomal recessive metabolic disorder caused by a deficiency of enzyme arginase I.
      explanation: Confirms autosomal recessive inheritance in an independent clinical cohort.
  variants:
  - name: Various ARG1 pathogenic variants
    description: 'More than 40 pathogenic mutations have been identified across the ARG1 gene on chromosome 6q23, distributed fairly uniformly throughout the gene. Variants include missense, nonsense, frameshift, and splice-site mutations resulting in partial or complete loss of enzyme function.

      '
    gene:
      preferred_term: ARG1
      term:
        id: hgnc:663
        label: ARG1
  features: 'Biallelic pathogenic variants in ARG1 cause loss of arginase 1 enzyme activity. The gene is located on chromosome 6q23 and encodes a trimeric manganese-dependent metalloprotein. Genotype-phenotype correlations are incomplete, but complete loss of function generally leads to more severe disease. Residual enzyme activity may account for clinical variability. More than 73 published ARG1 variants have been identified, of which 46 are classified as pathogenic or likely pathogenic.

    '
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea.
    explanation: Describes the genetic basis including mutation spectrum and functional consequences.
  - reference: CGGV:assertion_0157f793-9232-4700-bbf0-dfb16270f688-2020-06-29T174101.533Z
    reference_title: "ARG1 / hyperargininemia (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ARG1 | HGNC:663 | hyperargininemia | MONDO:0008814 | AR | Definitive"
    explanation: ClinGen classifies the ARG1-hyperargininemia gene-disease relationship as definitive with autosomal recessive inheritance.
treatments:
- name: Protein-restricted diet
  description: 'Dietary protein restriction with supplementation of essential amino acids is the cornerstone of chronic management. The primary goal is to reduce plasma arginine concentration below 200 umol/L, though this target is rarely achievable with diet alone due to endogenous arginine production.

    '
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  notes: Dietary protein restriction is a well-established cornerstone of ARG1 deficiency management, but direct evidence for its efficacy from controlled trials is lacking. The pegzilarginase trial was motivated in part by the insufficiency of diet alone to normalize plasma arginine.
  target_mechanisms:
  - target: Impaired ureagenesis and hyperargininemia
    treatment_effect: MODULATES
    description: Protein restriction reduces arginine intake and nitrogen load, addressing the hyperargininemia mechanism.
  target_phenotypes:
  - preferred_term: Hyperargininemia
    term:
      id: HP:0500153
      label: Hyperargininemia
- name: Nitrogen scavenger therapy
  description: 'Nitrogen scavengers including sodium benzoate, sodium phenylbutyrate, and sodium phenylacetate are used to provide alternative pathways for nitrogen excretion, particularly during hyperammonemic episodes and as chronic adjunctive therapy.

    '
  treatment_term:
    preferred_term: nitrogen scavenger therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  notes: Nitrogen scavengers are a standard part of UCD management, used adjunctively with dietary protein restriction. Direct trial evidence specific to ARG1 deficiency is limited compared to other UCDs.
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
- name: Pegzilarginase enzyme replacement therapy
  description: 'Pegzilarginase is a pegylated recombinant human arginase 1 enzyme therapy that represents the first potential disease-modifying treatment for ARG1-D. In the Phase 3 PEACE trial, weekly pegzilarginase reduced geometric mean plasma arginine from 354 to 86 umol/L at 24 weeks, normalizing levels in 90.5% of patients compared to 0% with placebo, with clinically relevant functional mobility improvements.

    '
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:38292042
    reference_title: "Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition, clinically relevant functional mobility improvements were demonstrated with pegzilarginase treatment. These effects were sustained long-term through additional 24 weeks of subsequent exposure.
    explanation: Demonstrates sustained clinical mobility improvements beyond biochemical correction.
  target_mechanisms:
  - target: Impaired ureagenesis and hyperargininemia
    treatment_effect: RESTORES
    description: Pegzilarginase supplies arginase activity to normalize plasma arginine.
    evidence:
    - reference: PMID:38292042
      reference_title: "Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Pegzilarginase lowered geometric mean pArg from 354.0 μmol/L to 86.4 μmol/L at Week 24 vs 464.7 to 426.6 μmol/L for placebo
      explanation: Directly supports pegzilarginase correction of the hyperargininemia mechanism.
  target_phenotypes:
  - preferred_term: Hyperargininemia
    term:
      id: HP:0500153
      label: Hyperargininemia
  - preferred_term: Spastic paraparesis
    term:
      id: HP:0002313
      label: Spastic paraparesis
- name: Liver transplantation
  description: 'Liver transplantation can restore hepatic urea cycle function and halt neurological deterioration. It is considered for patients with severe metabolic instability refractory to medical management.

    '
  treatment_term:
    preferred_term: liver transplantation
    term:
      id: MAXO:0001175
      label: liver transplantation
  target_mechanisms:
  - target: Impaired ureagenesis and hyperargininemia
    treatment_effect: RESTORES
    description: Liver transplantation can restore hepatic urea-cycle function in severe urea-cycle disorders.
- name: Antispasticity management
  description: 'Symptomatic treatment of spasticity with physical therapy, botulinum toxin injections, and oral antispasticity agents to maintain mobility and prevent contractures. Early intervention is important given the progressive nature of the motor involvement.

    '
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:22633632
    reference_title: "Clinical features and neurologic progression of hyperargininemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperargininemia is one of the few treatable causes of pediatric spastic paraparesis, and can be confused with cerebral palsy.
    explanation: Identifying the treatable nature of spasticity supports active spasticity management.
  target_phenotypes:
  - preferred_term: Spastic paraparesis
    term:
      id: HP:0002313
      label: Spastic paraparesis
  - preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
- name: Antiepileptic therapy
  description: 'Seizure management with appropriate antiepileptic drugs, given that seizures occur in 60-75% of patients. Seizure control is an important aspect of supportive care.

    '
  notes: Valproic acid should be avoided in ARG1 deficiency because it can exacerbate hyperammonemia.
  treatment_term:
    preferred_term: antiepileptic drug therapy
    term:
      id: MAXO:0000167
      label: anticonvulsant agent therapy
  evidence:
  - reference: PMID:22633632
    reference_title: "Clinical features and neurologic progression of hyperargininemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seizures in hyperargininemia may be more common than reported in previous studies.
    explanation: High seizure frequency supports the need for antiepileptic management.
  - reference: PMID:20301338
    reference_title: "Arginase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Agents/circumstances to avoid: Valproic acid (exacerbates hyperammonemia)."
    explanation: GeneReviews identifies valproic acid as an agent to avoid because it can exacerbate hyperammonemia.
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
- name: Newborn screening
  description: 'Arginase deficiency is detectable by newborn screening using tandem mass spectrometry with elevated arginine as the primary marker. Use of the arginine-to-ornithine ratio improves sensitivity and specificity, as neonatal arginine levels may appear near-normal due to maternal arginase or ARG2 activity.

    '
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  evidence:
  - reference: PMID:28659245
    reference_title: "Newborn screening for hyperargininemia due to arginase 1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Improved newborn screening effectiveness should lead to better case detection and more rapid treatment to lower plasma arginine levels hence improving long term outcome of individuals with hyperargininemia.
    explanation: Supports early detection through newborn screening for improved outcomes.
  target_phenotypes:
  - preferred_term: Hyperargininemia
    term:
      id: HP:0500153
      label: Hyperargininemia
- name: Genetic counseling
  description: 'Genetic counseling for affected families including discussion of autosomal recessive inheritance, 25% recurrence risk, carrier testing, and prenatal diagnostic options. Carrier screening implications are increasingly recognized given the expanding understanding of ARG1 variant pathogenicity.

    '
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  target_mechanisms:
  - target: ARG1 pathogenic variants
    treatment_effect: MODULATES
    description: Counseling and reproductive testing are anchored to the family's ARG1 pathogenic variants.
    evidence:
    - reference: PMID:20301338
      reference_title: "Arginase Deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the ARG1 pathogenic variants in the family are known.
      explanation: GeneReviews supports carrier and prenatal testing when familial ARG1 variants are known.
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle, leading to impaired ureagenesis.
    explanation: Autosomal recessive inheritance pattern supports the role of genetic counseling.
  - reference: PMID:20301338
    reference_title: "Arginase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GENETIC COUNSELING: Arginase deficiency is inherited in an autosomal recessive manner."
    explanation: GeneReviews directly supports genetic counseling for autosomal recessive inheritance.
notes: 'Key distinguishing features of ARG1 deficiency among urea cycle disorders: (1) hyperammonemia is infrequent rather than dominant; (2) progressive spastic paraparesis is the hallmark presentation; (3) the disease is often initially confused with cerebral palsy or hereditary spastic paraplegia; (4) chronic arginine toxicity and guanidino compound accumulation drive neurological injury rather than acute ammonia crises. The Phase 3 PEACE trial of pegzilarginase represents a major advance, demonstrating that sustained arginine normalization is achievable and associated with functional mobility improvements. Gene therapy and mRNA therapeutic approaches are in preclinical development. Caution is warranted in extrapolating mouse model findings, as the lethal disease phenotype in mice is substantially more severe than in humans.

  '
references:
- reference: PMID:20301338
  title: "Arginase Deficiency."
  tags:
  - GeneReviews
- reference: DOI:10.1002/jimd.12609
  title: 'Gene therapy for urea cycle defects: An update from historical perspectives to future prospects'
  found_in:
  - Arginase_Deficiency-deep-research-falcon.md
  findings:
  - statement: 'Gene therapy for urea cycle defects: An update from historical perspectives to future prospects'
    supporting_text: Urea cycle defects (UCDs) are severe inherited metabolic diseases with high unmet needs which present a permanent risk of hyperammonaemic decompensation and subsequent acute death or neurological sequelae, when treated with conventional dietetic and medical therapies.
- reference: DOI:10.1002/jimd.12807
  title: Exploring <scp>RNA</scp> therapeutics for urea cycle disorders
  found_in:
  - Arginase_Deficiency-deep-research-falcon.md
  findings:
  - statement: RNA has triggered a significant shift in modern medicine, providing a promising way to revolutionize disease treatment methods.
    supporting_text: RNA has triggered a significant shift in modern medicine, providing a promising way to revolutionize disease treatment methods.
- reference: PMID:11148548
  title: The nutritional management of urea cycle disorders.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2001 Jan;138(1 Suppl):S40-4;discussion S44-5. doi: 10.1067/mpd.2001.111835.'
    supporting_text: '2001 Jan;138(1 Suppl):S40-4;discussion S44-5. doi: 10.1067/mpd.2001.111835.'
- reference: PMID:18321250
  title: Neuroimaging findings in hyperargininemia.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2008 Oct;18(4):457-62. doi: 10.1111/j.1552-6569.2007.00217.x.'
    supporting_text: '2008 Oct;18(4):457-62. doi: 10.1111/j.1552-6569.2007.00217.x.'
- reference: PMID:19381865
  title: 'Early-onset hyperargininaemia: a severe disorder?'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2009 Dec;32 Suppl 1:S175-8. doi: 10.1007/s10545-009-1137-5.'
    supporting_text: '2009 Dec;32 Suppl 1:S175-8. doi: 10.1007/s10545-009-1137-5.'
- reference: PMID:20025860
  title: Clinical and biochemical characteristics of patients with urea cycle disorders in a developing country.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2010 Mar;43(4-5):461-6. doi: 10.1016/j.clinbiochem.2009.12.004.'
    supporting_text: '2010 Mar;43(4-5):461-6. doi: 10.1016/j.clinbiochem.2009.12.004.'
- reference: PMID:20456883
  title: A long-term survival case of arginase deficiency with severe multicystic white matter and compound mutations.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2011 Jan;33(1):45-8. doi: 10.1016/j.braindev.2010.03.001.'
    supporting_text: '2011 Jan;33(1):45-8. doi: 10.1016/j.braindev.2010.03.001.'
- reference: PMID:21229317
  title: 'Neonatal cholestasis: an uncommon presentation of hyperargininemia.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2010 Dec;33 Suppl 3:S503-6. doi: 10.1007/s10545-010-9263-7.'
    supporting_text: '2010 Dec;33 Suppl 3:S503-6. doi: 10.1007/s10545-010-9263-7.'
- reference: PMID:22959135
  title: Analysis of novel ARG1 mutations causing hyperargininemia and correlation with arginase I activity in erythrocytes.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2012 Nov 1;509(1):124-30. doi: 10.1016/j.gene.2012.08.003.'
    supporting_text: '2012 Nov 1;509(1):124-30. doi: 10.1016/j.gene.2012.08.003.'
- reference: PMID:23327293
  title: Impact of substrate protonation and tautomerization states on interactions with the active site of arginase I.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2013 Feb 25;53(2):452-60. doi: 10.1021/ci300506y.'
    supporting_text: '2013 Feb 25;53(2):452-60. doi: 10.1021/ci300506y.'
- reference: PMID:23920045
  title: Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2013 Nov;110(3):222-30. doi: 10.1016/j.ymgme.2013.06.020.'
    supporting_text: '2013 Nov;110(3):222-30. doi: 10.1016/j.ymgme.2013.06.020.'
- reference: PMID:24113687
  title: 'Dietary management of urea cycle disorders: European practice.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: There is no published data comparing dietary management of urea cycle disorders (UCD) in different countries.
    supporting_text: There is no published data comparing dietary management of urea cycle disorders (UCD) in different countries.
- reference: PMID:25007099
  title: Crystal structure of Schistosoma mansoni arginase, a potential drug target for the treatment of schistosomiasis.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2014 Jul 22;53(28):4671-84. doi: 10.1021/bi5004519.'
    supporting_text: '2014 Jul 22;53(28):4671-84. doi: 10.1021/bi5004519.'
- reference: PMID:25474440
  title: Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2015 Feb;22(2):111-5. doi: 10.1038/gt.2014.106.'
    supporting_text: '2015 Feb;22(2):111-5. doi: 10.1038/gt.2014.106.'
- reference: PMID:27335400
  title: Rescue of the Functional Alterations of Motor Cortical Circuits in Arginase Deficiency by Neonatal Gene Therapy.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2016 Jun 22;36(25):6680-90. doi: 10.1523/JNEUROSCI.0897-16.2016.'
    supporting_text: '2016 Jun 22;36(25):6680-90. doi: 10.1523/JNEUROSCI.0897-16.2016.'
- reference: PMID:27761413
  title: Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2016 Oct 12;9:54-60. doi: 10.1016/j.ymgmr.2016.10.003. eCollection 2016 Dec.'
    supporting_text: '2016 Oct 12;9:54-60. doi: 10.1016/j.ymgmr.2016.10.003. eCollection 2016 Dec.'
- reference: PMID:27898091
  title: Restoring Ureagenesis in Hepatocytes by CRISPR/Cas9-mediated Genomic Addition to Arginase-deficient Induced Pluripotent Stem Cells.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2016 Nov 29;5(11):e394. doi: 10.1038/mtna.2016.98.'
    supporting_text: '2016 Nov 29;5(11):e394. doi: 10.1038/mtna.2016.98.'
- reference: PMID:29724658
  title: Human hepatocyte transplantation corrects the inherited metabolic liver disorder arginase deficiency in mice.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2018 Jun;124(2):114-123. doi: 10.1016/j.ymgme.2018.04.005.'
    supporting_text: '2018 Jun;124(2):114-123. doi: 10.1016/j.ymgme.2018.04.005.'
- reference: PMID:35236361
  title: 'Arginase 1 Deficiency: using genetic databases as a tool to establish global prevalence.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2022 Mar 2;17(1):94. doi: 10.1186/s13023-022-02226-8.'
    supporting_text: '2022 Mar 2;17(1):94. doi: 10.1186/s13023-022-02226-8.'
- reference: PMID:35695271
  title: 'Health care resource utilization in the management of patients with Arginase 1 Deficiency in the US: a retrospective, observational, claims database study.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Arginase 1 Deficiency (ARG1-D) is an inherited metabolic disease that leads to significant morbidity.
    supporting_text: Arginase 1 Deficiency (ARG1-D) is an inherited metabolic disease that leads to significant morbidity.
- reference: PMID:35822089
  title: 'Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Arginase 1 deficiency (ARG1-D) is a rare, progressive and debilitating urea cycle disorder characterized by clinical manifestations including spasticity, seizures, developmental delay, and intellectual disability.
    supporting_text: Arginase 1 deficiency (ARG1-D) is a rare, progressive and debilitating urea cycle disorder characterized by clinical manifestations including spasticity, seizures, developmental delay, and intellectual disability.
- reference: PMID:36049366
  title: 'Epidemiology, methods of diagnosis, and clinical management of patients with arginase 1 deficiency (ARG1-D): A systematic review.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Arginase 1 Deficiency (ARG1-D) is a rare, progressive, metabolic disorder that is characterized by devastating manifestations driven by elevated plasma arginine levels.
    supporting_text: Arginase 1 Deficiency (ARG1-D) is a rare, progressive, metabolic disorder that is characterized by devastating manifestations driven by elevated plasma arginine levels.
- reference: PMID:36175366
  title: The role and control of arginine levels in arginase 1 deficiency.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2023 Jan;46(1):3-14. doi: 10.1002/jimd.12564.'
    supporting_text: '2023 Jan;46(1):3-14. doi: 10.1002/jimd.12564.'
- reference: PMID:36474391
  title: A Delayed Presentation of Arginase Deficiency Presenting with Status Epilepticus.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2022 Dec;32(12):1629-1631. doi: 10.29271/jcpsp.2022.12.1629.'
    supporting_text: '2022 Dec;32(12):1629-1631. doi: 10.29271/jcpsp.2022.12.1629.'
- reference: PMID:36698992
  title: Arginase 1 Deficiency in Patients Initially Diagnosed with Hereditary Spastic Paraplegia.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Arginase 1 Deficiency (ARG1-D) is a rare autosomal recessive urea cycle disorder (UCD) characterized by pathologic elevation of plasma arginine and debilitating manifestations.
    supporting_text: Arginase 1 Deficiency (ARG1-D) is a rare autosomal recessive urea cycle disorder (UCD) characterized by pathologic elevation of plasma arginine and debilitating manifestations.
- reference: PMID:36722221
  title: 'Arginase deficiency in Bulgaria: first cases and potential endemic region for the disorder.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Atemin S(1), Todorov T, Tourtourikov I, Ivanova MB, Chamova T, Avdjieva-Tzavella D, Kathom H, Georgieva B, Guergueltcheva V, Savov IBA, Tournev I, Mitev V, Todorova A.
    supporting_text: Atemin S(1), Todorov T, Tourtourikov I, Ivanova MB, Chamova T, Avdjieva-Tzavella D, Kathom H, Georgieva B, Guergueltcheva V, Savov IBA, Tournev I, Mitev V, Todorova A.
- reference: PMID:36726215
  title: 'Guanidinoacetate (GAA) is a potent GABA(A) receptor GABA mimetic: Implications for neurological disease pathology.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2023 May;165(3):445-454. doi: 10.1111/jnc.15774.'
    supporting_text: '2023 May;165(3):445-454. doi: 10.1111/jnc.15774.'
- reference: PMID:37243436
  title: Arginase deficiency-An unheralded cause of developmental epileptic encephalopathy.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2023 Aug;25(4):556-561. doi: 10.1002/epd2.20081.'
    supporting_text: '2023 Aug;25(4):556-561. doi: 10.1002/epd2.20081.'
- reference: PMID:38584907
  title: 'Hyperargininemia: A Rare Diagnosis in Adulthood.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Hyperargininemia is a rare inherited metabolic disorder of the urea cycle with an autosomal recessive transmission.
    supporting_text: Hyperargininemia is a rare inherited metabolic disorder of the urea cycle with an autosomal recessive transmission.
- reference: PMID:39567422
  title: Potential role of ARG1 c.57G > A variant in Argininemia.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2025 Feb;47(2):197-205. doi: 10.1007/s13258-024-01595-7.'
    supporting_text: '2025 Feb;47(2):197-205. doi: 10.1007/s13258-024-01595-7.'
- reference: PMID:40285952
  title: 'Urea cycle defects in adulthood: clinical presentation, diagnosis and treatment in genetically encoded hepatic metabolic disorders with a potential for encephalopathy.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2025 Apr 26;40(5):192. doi: 10.1007/s11011-025-01619-5.'
    supporting_text: '2025 Apr 26;40(5):192. doi: 10.1007/s11011-025-01619-5.'
- reference: PMID:40714964
  title: 'Long-Term Efficacy and Tolerability of Pegzilarginase in Arginase 1 Deficiency: Results of Two International Multicentre Open-Label Extension Studies.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2025 Jul;48(4):e70066. doi: 10.1002/jimd.70066.'
    supporting_text: '2025 Jul;48(4):e70066. doi: 10.1002/jimd.70066.'
- reference: PMID:41651652
  title: 'Clinical Characteristics of Arginase 1 Deficiency: Natural History Insights From International Clinical Trials.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2026 Mar;49(2):e70156. doi: 10.1002/jimd.70156.'
    supporting_text: '2026 Mar;49(2):e70156. doi: 10.1002/jimd.70156.'
- reference: PMID:41684183
  title: 'Cluster of Severe Arginase 1 Deficiency in the Comoros: Clinical, Neuroimaging, and Molecular Features in 17 Patients From Mayotte Compared With 10 From Paris.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2026 Mar;49(2):e70159. doi: 10.1002/jimd.70159.'
    supporting_text: '2026 Mar;49(2):e70159. doi: 10.1002/jimd.70159.'
- reference: DOI:10.1016/j.eclinm.2023.102405
  title: 'Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial'
  found_in:
  - Arginase_Deficiency-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/app14041647
  title: 'Argininemia: Pathophysiology and Novel Methods for Evaluation of the Disease'
  found_in:
  - Arginase_Deficiency-deep-research-falcon.md
  findings: []
- reference: PMID:26467175
  title: Arginase-1 deficiency.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings: []
- reference: PMID:28659245
  title: Newborn screening for hyperargininemia due to arginase 1 deficiency.
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings: []
- reference: PMID:38292042
  title: 'Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial.'
  found_in:
  - Arginase_Deficiency-deep-research-openscientist.md
  findings: []
📚

References & Deep Research

References

40
PMID:20301338
Arginase Deficiency.
No top-level findings curated for this source.
DOI:10.1002/jimd.12609
Gene therapy for urea cycle defects: An update from historical perspectives to future prospects
1 finding
Gene therapy for urea cycle defects: An update from historical perspectives to future prospects
"Urea cycle defects (UCDs) are severe inherited metabolic diseases with high unmet needs which present a permanent risk of hyperammonaemic decompensation and subsequent acute death or neurological sequelae, when treated with conventional dietetic and medical therapies."
DOI:10.1002/jimd.12807
Exploring <scp>RNA</scp> therapeutics for urea cycle disorders
1 finding
RNA has triggered a significant shift in modern medicine, providing a promising way to revolutionize disease treatment methods.
"RNA has triggered a significant shift in modern medicine, providing a promising way to revolutionize disease treatment methods."
PMID:11148548
The nutritional management of urea cycle disorders.
1 finding
2001 Jan;138(1 Suppl):S40-4;discussion S44-5. doi: 10.1067/mpd.2001.111835.
"2001 Jan;138(1 Suppl):S40-4;discussion S44-5. doi: 10.1067/mpd.2001.111835."
PMID:18321250
Neuroimaging findings in hyperargininemia.
1 finding
2008 Oct;18(4):457-62. doi: 10.1111/j.1552-6569.2007.00217.x.
"2008 Oct;18(4):457-62. doi: 10.1111/j.1552-6569.2007.00217.x."
PMID:19381865
Early-onset hyperargininaemia: a severe disorder?
1 finding
2009 Dec;32 Suppl 1:S175-8. doi: 10.1007/s10545-009-1137-5.
"2009 Dec;32 Suppl 1:S175-8. doi: 10.1007/s10545-009-1137-5."
PMID:20025860
Clinical and biochemical characteristics of patients with urea cycle disorders in a developing country.
1 finding
2010 Mar;43(4-5):461-6. doi: 10.1016/j.clinbiochem.2009.12.004.
"2010 Mar;43(4-5):461-6. doi: 10.1016/j.clinbiochem.2009.12.004."
PMID:20456883
A long-term survival case of arginase deficiency with severe multicystic white matter and compound mutations.
1 finding
2011 Jan;33(1):45-8. doi: 10.1016/j.braindev.2010.03.001.
"2011 Jan;33(1):45-8. doi: 10.1016/j.braindev.2010.03.001."
PMID:21229317
Neonatal cholestasis: an uncommon presentation of hyperargininemia.
1 finding
2010 Dec;33 Suppl 3:S503-6. doi: 10.1007/s10545-010-9263-7.
"2010 Dec;33 Suppl 3:S503-6. doi: 10.1007/s10545-010-9263-7."
PMID:22959135
Analysis of novel ARG1 mutations causing hyperargininemia and correlation with arginase I activity in erythrocytes.
1 finding
2012 Nov 1;509(1):124-30. doi: 10.1016/j.gene.2012.08.003.
"2012 Nov 1;509(1):124-30. doi: 10.1016/j.gene.2012.08.003."
PMID:23327293
Impact of substrate protonation and tautomerization states on interactions with the active site of arginase I.
1 finding
2013 Feb 25;53(2):452-60. doi: 10.1021/ci300506y.
"2013 Feb 25;53(2):452-60. doi: 10.1021/ci300506y."
PMID:23920045
Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse.
1 finding
2013 Nov;110(3):222-30. doi: 10.1016/j.ymgme.2013.06.020.
"2013 Nov;110(3):222-30. doi: 10.1016/j.ymgme.2013.06.020."
PMID:24113687
Dietary management of urea cycle disorders: European practice.
1 finding
There is no published data comparing dietary management of urea cycle disorders (UCD) in different countries.
"There is no published data comparing dietary management of urea cycle disorders (UCD) in different countries."
PMID:25007099
Crystal structure of Schistosoma mansoni arginase, a potential drug target for the treatment of schistosomiasis.
1 finding
2014 Jul 22;53(28):4671-84. doi: 10.1021/bi5004519.
"2014 Jul 22;53(28):4671-84. doi: 10.1021/bi5004519."
PMID:25474440
Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy.
1 finding
2015 Feb;22(2):111-5. doi: 10.1038/gt.2014.106.
"2015 Feb;22(2):111-5. doi: 10.1038/gt.2014.106."
PMID:27335400
Rescue of the Functional Alterations of Motor Cortical Circuits in Arginase Deficiency by Neonatal Gene Therapy.
1 finding
2016 Jun 22;36(25):6680-90. doi: 10.1523/JNEUROSCI.0897-16.2016.
"2016 Jun 22;36(25):6680-90. doi: 10.1523/JNEUROSCI.0897-16.2016."
PMID:27761413
Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency.
1 finding
2016 Oct 12;9:54-60. doi: 10.1016/j.ymgmr.2016.10.003. eCollection 2016 Dec.
"2016 Oct 12;9:54-60. doi: 10.1016/j.ymgmr.2016.10.003. eCollection 2016 Dec."
PMID:27898091
Restoring Ureagenesis in Hepatocytes by CRISPR/Cas9-mediated Genomic Addition to Arginase-deficient Induced Pluripotent Stem Cells.
1 finding
2016 Nov 29;5(11):e394. doi: 10.1038/mtna.2016.98.
"2016 Nov 29;5(11):e394. doi: 10.1038/mtna.2016.98."
PMID:29724658
Human hepatocyte transplantation corrects the inherited metabolic liver disorder arginase deficiency in mice.
1 finding
2018 Jun;124(2):114-123. doi: 10.1016/j.ymgme.2018.04.005.
"2018 Jun;124(2):114-123. doi: 10.1016/j.ymgme.2018.04.005."
PMID:35236361
Arginase 1 Deficiency: using genetic databases as a tool to establish global prevalence.
1 finding
2022 Mar 2;17(1):94. doi: 10.1186/s13023-022-02226-8.
"2022 Mar 2;17(1):94. doi: 10.1186/s13023-022-02226-8."
PMID:35695271
Health care resource utilization in the management of patients with Arginase 1 Deficiency in the US: a retrospective, observational, claims database study.
1 finding
Arginase 1 Deficiency (ARG1-D) is an inherited metabolic disease that leads to significant morbidity.
"Arginase 1 Deficiency (ARG1-D) is an inherited metabolic disease that leads to significant morbidity."
PMID:35822089
Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports.
1 finding
Arginase 1 deficiency (ARG1-D) is a rare, progressive and debilitating urea cycle disorder characterized by clinical manifestations including spasticity, seizures, developmental delay, and intellectual disability.
"Arginase 1 deficiency (ARG1-D) is a rare, progressive and debilitating urea cycle disorder characterized by clinical manifestations including spasticity, seizures, developmental delay, and intellectual disability."
PMID:36049366
Epidemiology, methods of diagnosis, and clinical management of patients with arginase 1 deficiency (ARG1-D): A systematic review.
1 finding
Arginase 1 Deficiency (ARG1-D) is a rare, progressive, metabolic disorder that is characterized by devastating manifestations driven by elevated plasma arginine levels.
"Arginase 1 Deficiency (ARG1-D) is a rare, progressive, metabolic disorder that is characterized by devastating manifestations driven by elevated plasma arginine levels."
PMID:36175366
The role and control of arginine levels in arginase 1 deficiency.
1 finding
2023 Jan;46(1):3-14. doi: 10.1002/jimd.12564.
"2023 Jan;46(1):3-14. doi: 10.1002/jimd.12564."
PMID:36474391
A Delayed Presentation of Arginase Deficiency Presenting with Status Epilepticus.
1 finding
2022 Dec;32(12):1629-1631. doi: 10.29271/jcpsp.2022.12.1629.
"2022 Dec;32(12):1629-1631. doi: 10.29271/jcpsp.2022.12.1629."
PMID:36698992
Arginase 1 Deficiency in Patients Initially Diagnosed with Hereditary Spastic Paraplegia.
1 finding
Arginase 1 Deficiency (ARG1-D) is a rare autosomal recessive urea cycle disorder (UCD) characterized by pathologic elevation of plasma arginine and debilitating manifestations.
"Arginase 1 Deficiency (ARG1-D) is a rare autosomal recessive urea cycle disorder (UCD) characterized by pathologic elevation of plasma arginine and debilitating manifestations."
PMID:36722221
Arginase deficiency in Bulgaria: first cases and potential endemic region for the disorder.
1 finding
Atemin S(1), Todorov T, Tourtourikov I, Ivanova MB, Chamova T, Avdjieva-Tzavella D, Kathom H, Georgieva B, Guergueltcheva V, Savov IBA, Tournev I, Mitev V, Todorova A.
"Atemin S(1), Todorov T, Tourtourikov I, Ivanova MB, Chamova T, Avdjieva-Tzavella D, Kathom H, Georgieva B, Guergueltcheva V, Savov IBA, Tournev I, Mitev V, Todorova A."
PMID:36726215
Guanidinoacetate (GAA) is a potent GABA(A) receptor GABA mimetic: Implications for neurological disease pathology.
1 finding
2023 May;165(3):445-454. doi: 10.1111/jnc.15774.
"2023 May;165(3):445-454. doi: 10.1111/jnc.15774."
PMID:37243436
Arginase deficiency-An unheralded cause of developmental epileptic encephalopathy.
1 finding
2023 Aug;25(4):556-561. doi: 10.1002/epd2.20081.
"2023 Aug;25(4):556-561. doi: 10.1002/epd2.20081."
PMID:38584907
Hyperargininemia: A Rare Diagnosis in Adulthood.
1 finding
Hyperargininemia is a rare inherited metabolic disorder of the urea cycle with an autosomal recessive transmission.
"Hyperargininemia is a rare inherited metabolic disorder of the urea cycle with an autosomal recessive transmission."
PMID:39567422
Potential role of ARG1 c.57G > A variant in Argininemia.
1 finding
2025 Feb;47(2):197-205. doi: 10.1007/s13258-024-01595-7.
"2025 Feb;47(2):197-205. doi: 10.1007/s13258-024-01595-7."
PMID:40285952
Urea cycle defects in adulthood: clinical presentation, diagnosis and treatment in genetically encoded hepatic metabolic disorders with a potential for encephalopathy.
1 finding
2025 Apr 26;40(5):192. doi: 10.1007/s11011-025-01619-5.
"2025 Apr 26;40(5):192. doi: 10.1007/s11011-025-01619-5."
PMID:40714964
Long-Term Efficacy and Tolerability of Pegzilarginase in Arginase 1 Deficiency: Results of Two International Multicentre Open-Label Extension Studies.
1 finding
2025 Jul;48(4):e70066. doi: 10.1002/jimd.70066.
"2025 Jul;48(4):e70066. doi: 10.1002/jimd.70066."
PMID:41651652
Clinical Characteristics of Arginase 1 Deficiency: Natural History Insights From International Clinical Trials.
1 finding
2026 Mar;49(2):e70156. doi: 10.1002/jimd.70156.
"2026 Mar;49(2):e70156. doi: 10.1002/jimd.70156."
PMID:41684183
Cluster of Severe Arginase 1 Deficiency in the Comoros: Clinical, Neuroimaging, and Molecular Features in 17 Patients From Mayotte Compared With 10 From Paris.
1 finding
2026 Mar;49(2):e70159. doi: 10.1002/jimd.70159.
"2026 Mar;49(2):e70159. doi: 10.1002/jimd.70159."
DOI:10.1016/j.eclinm.2023.102405
Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial
No top-level findings curated for this source.
DOI:10.3390/app14041647
Argininemia: Pathophysiology and Novel Methods for Evaluation of the Disease
No top-level findings curated for this source.
PMID:26467175
Arginase-1 deficiency.
No top-level findings curated for this source.
PMID:28659245
Newborn screening for hyperargininemia due to arginase 1 deficiency.
No top-level findings curated for this source.
PMID:38292042
Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial.
No top-level findings curated for this source.

Deep Research

2
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 31 citations 2026-02-23T23:37:34.775398

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Arginase Deficiency
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Arginase Deficiency. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Title: Pathophysiology of Arginase 1 Deficiency (Argininemia / Hyperargininemia): Molecular and Cellular Mechanisms, Disease Course, and 2023–2024 Translational Updates

Publication window prioritized: 2024 primary and review literature, plus ClinicalTrials.gov entries.

  1. Disease identity, key concepts, and definitions (current understanding)

Disease name and ontology - Arginase 1 deficiency (ARG1-D), also called argininemia or hyperargininemia, is an autosomal recessive urea cycle disorder caused by biallelic pathogenic variants in ARG1 (arginase 1), the final enzyme of the urea cycle. (russo2024efficacyandsafety pages 1-2, nteli2024argininemiapathophysiologyand pages 2-3) - MONDO: arginase deficiency = MONDO_0008814 (Open Targets output). (nteli2024argininemiapathophysiologyand pages 7-8)

Core biochemical definition - ARG1 catalyzes the final urea cycle step, “hydrolysis of L-arginine to ornithine and urea.” (nteli2024argininemiapathophysiologyand pages 2-3) - Loss of hepatic ARG1 activity leads to persistent hyperargininemia and accumulation of downstream nitrogenous metabolites, including guanidino compounds (GCs), with intermittent episodic hyperammonemia in some contexts. (nteli2024argininemiapathophysiologyand pages 2-3, nteli2024argininemiapathophysiologyand pages 3-5)

Key “pathophysiological driver” concept - In the 2024 phase 3 pegzilarginase PEACE trial paper, arginine is explicitly framed as the central driver: “Arginine: the key driver of patophysiology and progression in arginase 1 deficiency.” (russo2024efficacyandsafety pages 16-16)

  1. Core pathophysiology (molecular pathways and cellular processes)

2.1 Primary pathophysiological mechanism: impaired ureagenesis with hyperargininemia - ARG1 is predominantly a liver cytosolic enzyme, but is also present in erythrocytes, vasculature, and immune cells; it is described as a trimeric metalloprotein requiring Mn2+ for maximal activity and structural stabilization. (nteli2024argininemiapathophysiologyand pages 2-3) - ARG1 mutations reduce/ablate enzymatic activity, causing arginine accumulation and broader disruption of nitrogen disposal (“accumulation of arginine and other nitrogenous metabolites”), with hyperammonemia occurring less frequently than in many other urea cycle disorders but still clinically relevant during catabolic stress. (nteli2024argininemiapathophysiologyand pages 2-3, nteli2024argininemiapathophysiologyand pages 5-7)

Biomarker magnitudes and targets - Plasma arginine can be markedly elevated: “as high as four times the normal (>300 µmol/L),” and the “primary goal in argininemia is to reduce arginine concentration in plasma below 200 µmol/L.” (nteli2024argininemiapathophysiologyand pages 5-7)

2.2 Neurotoxicity: arginine-derivatives (guanidino compounds) and disrupted neurotransmission/ion homeostasis - The 2024 review emphasizes that accumulation of arginine, ammonia, and guanidino compounds act as neurotoxins contributing to neurological sequelae. (nteli2024argininemiapathophysiologyand pages 1-2, nteli2024argininemiapathophysiologyand pages 3-5) - Mechanistic neurotoxicity themes cited in the 2024 review include: - Inhibition of inhibitory neurotransmission: “Guanidino compounds that are increased in hyperargininemia inhibit GABA and glycine responses on mouse neurons in cell culture.” (russo2024efficacyandsafety pages 16-16) - Disruption of membrane ion pumps and cholinergic signaling via in vitro inhibitory effects on Na+,K+-ATPase and cholinesterases, and induction of oxidative stress in brain tissue models. (nteli2024argininemiapathophysiologyand pages 12-14)

2.3 White matter / myelination involvement (cellular and tissue pathology) - Central nervous system white matter pathology is supported by the review’s cited evidence of “dysmyelination” and corticospinal tract pathology, with oligodendrocyte degeneration/dysmyelination discussed as part of mechanistic interpretation for progressive spasticity. (nteli2024argininemiapathophysiologyand pages 2-3, nteli2024argininemiapathophysiologyand pages 3-5) - RNA-therapeutics review highlights preclinical evidence that addressing hepatic ARG1 deficiency can prevent CNS myelination defects in mice: “intermittent administration of LNPs carrying ARG1 mRNA significantly improved myelination in the central nervous system and managed ammonia and arginine levels in arginase-deficient mice.” (richard2024exploringrnatherapeutics pages 4-6)

2.4 Nitric oxide / polyamine pathway interface (dysregulated arginine utilization) - The 2024 review highlights pathway cross-talk: arginine is a common substrate for arginase and nitric oxide synthase (NOS), and cites work on the “Regulatory Role of Arginase I and II in Nitric Oxide, Polyamine, and Proline Syntheses in Endothelial Cells,” supporting the concept that ARG1 loss can perturb arginine partitioning into NO and polyamine-related pathways. (nteli2024argininemiapathophysiologyand pages 12-14)

  1. Key molecular players (genes/proteins, chemicals, cell types, anatomy)

3.1 Genes/proteins - Causal gene: ARG1 (arginase 1). (russo2024efficacyandsafety pages 1-2, nteli2024argininemiapathophysiologyand pages 2-3) - Disease genetics summary from 2024 review: ARG1 is on chromosome 6q23; “more than 43 pathogenic mutations have been identified.” (nteli2024argininemiapathophysiologyand pages 7-8)

3.2 Chemical entities / metabolites (with CHEBI-ready list) Key metabolites and small molecules implicated by the 2024 review and phase 3 trial: - L-arginine (CHEBI:29016) — primary elevated metabolite and disease driver. (russo2024efficacyandsafety pages 16-16, nteli2024argininemiapathophysiologyand pages 5-7) - Ornithine (CHEBI:15729) — reduced production due to impaired arginine hydrolysis; Arg/Orn ratio used diagnostically. (nteli2024argininemiapathophysiologyand pages 7-8) - Urea (CHEBI:16199) — reduced production due to impaired urea cycle output. (nteli2024argininemiapathophysiologyand pages 2-3) - Ammonia/ammonium (CHEBI:28938/CHEBI:7434) — episodic elevations during catabolic stress; less frequent than other UCDs. (nteli2024argininemiapathophysiologyand pages 2-3, nteli2024argininemiapathophysiologyand pages 5-7) - Guanidino compounds (group term; includes multiple guanidino-derivatives) — increased in ARG1-D; neurotoxic and measurable in blood/CSF/brain material. (russo2024efficacyandsafety pages 16-16, nteli2024argininemiapathophysiologyand pages 12-14)

Therapeutic chemical/biologic entities with real-world use - Nitrogen scavengers: benzoate, phenylbutyrate, phenylacetate. (nteli2024argininemiapathophysiologyand pages 5-7) - Pegzilarginase (pegylated recombinant human arginase 1 enzyme therapy). (russo2024efficacyandsafety pages 1-2)

3.3 Cell types (CL-ready examples supported by evidence) - Hepatocytes (liver is the central organ of ureagenesis; “hepatocyte arginase” deficiency is emphasized). (nteli2024argininemiapathophysiologyand pages 5-7) - Erythrocytes / red blood cells (ARG1 activity is measured in RBCs; ARG1 present in erythrocytes). (nteli2024argininemiapathophysiologyand pages 2-3, nteli2024argininemiapathophysiologyand pages 5-7) - Neurons (mouse neuron culture evidence for GABA/glycine response inhibition by increased guanidino compounds). (russo2024efficacyandsafety pages 16-16) - Oligodendrocytes (implicated by dysmyelination/white matter pathology discussed in review). (nteli2024argininemiapathophysiologyand pages 3-5) - Immune cells (ARG1 noted as present in immune cells such as M2-like macrophages). (nteli2024argininemiapathophysiologyand pages 2-3)

3.4 Anatomical locations (UBERON-ready examples) - Liver (UBERON:0002107) — primary site of ARG1-mediated urea cycle flux. (nteli2024argininemiapathophysiologyand pages 2-3) - Central nervous system / brain white matter (UBERON:0000955) — dysmyelination, corticospinal tract degeneration, and neuroimaging abnormalities. (nteli2024argininemiapathophysiologyand pages 2-3) - Cerebrospinal fluid (CSF) — arginine and guanidino compounds reported/assayed in CSF. (nteli2024argininemiapathophysiologyand pages 1-2, nteli2024argininemiapathophysiologyand pages 12-14)

  1. Biological processes (GO-oriented annotations)

The following GO process categories are directly motivated by the evidence summarized in 2024 sources: - Urea cycle / ureagenesis / nitrogen compound metabolic process: disruption due to impaired ARG1-mediated conversion of arginine to urea and ornithine. (nteli2024argininemiapathophysiologyand pages 2-3) - Arginine catabolic process: primary enzymatic lesion (ARG1 loss). (nteli2024argininemiapathophysiologyand pages 2-3) - Amino acid homeostasis: persistent hyperargininemia and altered Arg/Orn ratio. (nteli2024argininemiapathophysiologyand pages 5-7, nteli2024argininemiapathophysiologyand pages 7-8) - Neurotransmitter receptor activity modulation / synaptic transmission (inhibitory): guanidino compounds inhibit GABA and glycine responses in neurons (mechanistic evidence cited within the 2024 trial paper). (russo2024efficacyandsafety pages 16-16) - Oxidative stress response: excess arginine can induce oxidative stress; guanidino compounds stimulate oxidative stress in brain tissue models (as cited in the 2024 review). (nteli2024argininemiapathophysiologyand pages 3-5, nteli2024argininemiapathophysiologyand pages 12-14) - Myelination / CNS development: dysmyelination and evidence that ARG1 mRNA therapy can improve myelination in arginase-deficient mice. (nteli2024argininemiapathophysiologyand pages 3-5, richard2024exploringrnatherapeutics pages 4-6)

  1. Cellular components (where processes occur)

  2. Cytosol: ARG1 is described as a liver cytosolic enzyme; enzymatic conversion of arginine to ornithine and urea is cytosolic in hepatocytes. (nteli2024argininemiapathophysiologyand pages 2-3)

  3. Extracellular space / plasma: clinically measured hyperargininemia; plasma arginine is the primary biochemical endpoint in trials. (russo2024efficacyandsafety pages 1-2)
  4. Cerebrospinal fluid: guanidino compounds and arginine-related metabolites measured in CSF in ARG1-D. (russo2024efficacyandsafety pages 16-16, nteli2024argininemiapathophysiologyand pages 12-14)

  5. Neuronal membrane/synaptic contexts: functional inhibition of neurotransmitter responses (GABA/glycine) by guanidino compounds implies synaptic receptor-level dysfunction. (russo2024efficacyandsafety pages 16-16)

  6. Disease progression (sequence of events)

A mechanistically anchored progression model consistent with 2024 evidence: 1) Genetic lesion: biallelic ARG1 variants → reduced/absent ARG1 activity (hepatic predominant). (russo2024efficacyandsafety pages 1-2, nteli2024argininemiapathophysiologyand pages 2-3) 2) Early biochemical phase: persistent hyperargininemia develops; newborn screening may miss cases because “plasma arginine levels may appear normal or near-normal due to the lingering effects of maternal arginase or due to arginase 2,” motivating Arg/Orn ratio approaches. (nteli2024argininemiapathophysiologyand pages 5-7) 3) Metabolite toxicity phase: arginine and guanidino compound accumulation contributes to neurotoxicity (inhibitory neurotransmission perturbation, oxidative stress, ion pump effects) and white matter injury/dysmyelination. (nteli2024argininemiapathophysiologyand pages 12-14, nteli2024argininemiapathophysiologyand pages 3-5) 4) Clinical neurologic phase: progressive spastic diplegia/paraparesis emerges, often beginning in early childhood/first decade; seizures and cognitive/developmental issues are common; catabolic stress may trigger episodic hyperammonemia with encephalopathy risk. (nteli2024argininemiapathophysiologyand pages 2-3) 5) Chronic disability phase: progressive motor impairment and mobility limitation; neuroimaging changes (cerebral/cerebellar atrophy, corticospinal tract degeneration, dysmyelination). (nteli2024argininemiapathophysiologyand pages 2-3)

  1. Phenotypic manifestations and mechanism linkage (HP-oriented)

Common phenotypes and frequencies (from 2024 review) - Progressive spastic diplegia/paraparesis (hallmark; onset often late infancy/early childhood). (nteli2024argininemiapathophysiologyand pages 2-3) - Upper motor neuron involvement in ~80% of patients. (nteli2024argininemiapathophysiologyand pages 2-3) - Seizures in ~60–75% of patients. (nteli2024argininemiapathophysiologyand pages 2-3) - Developmental delay, cognitive impairment, and hepatic pathology. (nteli2024argininemiapathophysiologyand pages 1-2)

Mechanistic linkage - Spasticity/UMN signs are plausibly linked to corticospinal tract degeneration and dysmyelination described in the review. (nteli2024argininemiapathophysiologyand pages 2-3) - Seizures are linked in the review to “epileptogenic properties” of guanidino compounds. (nteli2024argininemiapathophysiologyand pages 3-5)

  1. Recent developments and latest research (2023–2024 prioritized)

8.1 Disease-modifying enzyme therapy: pegzilarginase (2024 phase 3 evidence) - PEACE phase 3 (eClinicalMedicine; publication Feb 2024; DOI: 10.1016/j.eclinm.2023.102405; URL: https://doi.org/10.1016/j.eclinm.2023.102405): randomized, double-blind, placebo-controlled, multi-centre trial; n=32 (21 pegzilarginase, 11 placebo). (russo2024efficacyandsafety pages 1-2) - Primary biochemical outcome: geometric mean plasma arginine decreased from 354.0 to 86.4 µmol/L at Week 24 on pegzilarginase, versus 464.7 to 426.6 µmol/L on placebo; normalization in 90.5% vs 0%. (russo2024efficacyandsafety pages 1-2) - Clinical outcomes: functional mobility improvements were reported and sustained, and hyperammonaemic events occurred less often in the pegzilarginase arm (36% placebo vs 14% pegzilarginase). (russo2024efficacyandsafety pages 15-16) - Visual evidence: Figure/Table region showing pArg reductions and mobility endpoints is available from the paper (Figure 2/Table 2). (russo2024efficacyandsafety media be435973, russo2024efficacyandsafety media f9206652)

8.2 RNA therapeutics for ARG1 deficiency (2024 JIMD review synthesis; preclinical) - Richard et al. (J Inherit Metab Dis; Oct 2024; DOI: 10.1002/jimd.12807; URL: https://doi.org/10.1002/jimd.12807) states: “mRNA therapies encapsulated in LNPs have emerged as promising treatments for various UCD,” and reports for ARG1 deficiency that “codon-optimized ARG1 mRNA encapsulated in LNPs led to 100% survival of arginase-deficient mice, restoring urea cycle activity and maintaining normal liver function without signs of hepatotoxicity.” (richard2024exploringrnatherapeutics pages 4-6) - The same review reports CNS benefit: “intermittent administration of LNPs carrying ARG1 mRNA significantly improved myelination in the central nervous system and managed ammonia and arginine levels in arginase-deficient mice.” (richard2024exploringrnatherapeutics pages 4-6)

8.3 Gene therapy and genome engineering (2024 JIMD review synthesis; preclinical) - Duff et al. (J Inherit Metab Dis; Apr 2024; DOI: 10.1002/jimd.12609; URL: https://doi.org/10.1002/jimd.12609) cites AAV-mediated ARG1 gene therapy studies in mice that achieved “Long-term survival of the juvenile lethal arginase-deficient mouse” and prevented neuropathology with normal cognitive development in a hyperargininemic mouse model. (duff2024genetherapyfor pages 11-12) - The same review cites CRISPR/Cas9 genomic addition approaches in patient-derived cellular models (“Restoring ureagenesis in hepatocytes by CRISPR/Cas9-mediated genomic addition to arginase-deficient induced pluripotent stem cells”). (duff2024genetherapyfor pages 11-12)

  1. Current applications and real-world implementations

9.1 Standard-of-care (implementation) - Standard-of-care is supportive and aims to lower arginine and reduce catabolic stress risk: “dietary protein restriction, essential amino acid supplementation, and symptomatic treatments,” with guideline target plasma arginine ≤200 µmol/L though “rarely achievable” with diet alone due to endogenous arginine sources. (russo2024efficacyandsafety pages 2-3) - The 2024 review also describes nitrogen scavenger use (benzoate, phenylbutyrate, phenylacetate), essential amino acid supplements, and supportive measures; liver transplantation can halt neurological deterioration. (nteli2024argininemiapathophysiologyand pages 5-7)

9.2 Clinical development and implementation readiness: pegzilarginase programs ClinicalTrials.gov records (URLs provided by registry identifier format) - NCT03921541 (Phase 3; PEACE): “Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency” (Aeglea Biotherapeutics; initial posting 2019; URL: https://clinicaltrials.gov/study/NCT03921541). (NCT03921541 chunk 3) - NCT02488044 (Phase 1/2; open-label; n=16): registry specifies key PD outcomes including decreases in plasma arginine and plasma guanidino compound levels; participants continued prescribed diet. (NCT02488044 chunk 1) - NCT03378531 (Phase 2 extension; open-label; n=14; completed 2022): long-term safety/tolerability/immunogenicity/PK/PD follow-up for pegzilarginase. (NCT03378531 chunk 1) - NCT06582524 (Phase 3; <24 months; open-label; actual enrollment 3; status completed; start 2024-08-30): primary outcome is plasma arginine change from baseline to 12 weeks; secondary includes safety, PK, ADAs, arginine/ornithine, and feasible functional assessment (GMFM-66). URL: https://clinicaltrials.gov/study/NCT06582524. (NCT06582524 chunk 1)

  1. Expert opinions and analysis (authoritative synthesis)

  2. Mechanistic consensus in 2024 sources: persistent hyperargininemia and accumulation of neurotoxic metabolites (guanidino compounds; sometimes ammonia during stress) are central to neurological disease, with white-matter/myelination pathology a key substrate for progressive spasticity. (nteli2024argininemiapathophysiologyand pages 1-2, nteli2024argininemiapathophysiologyand pages 2-3, nteli2024argininemiapathophysiologyand pages 3-5)

  3. Translational consensus in 2024 sources: correcting systemic arginine elevation is a rational disease-modifying approach; pegzilarginase demonstrates that sustained arginine normalization is achievable in a randomized controlled setting and is accompanied by functional mobility gains, supporting arginine lowering as a mechanism-linked therapeutic strategy. (russo2024efficacyandsafety pages 16-16, russo2024efficacyandsafety pages 1-2, russo2024efficacyandsafety pages 13-14)

  4. Future-facing consensus: non-viral LNP–mRNA approaches are positioned as promising, mutation-agnostic hepatic correction strategies with preclinical evidence of both survival benefit and CNS myelination improvement in arginase-deficient mice, but (per these excerpts) remain preclinical for ARG1 as of 2024. (richard2024exploringrnatherapeutics pages 4-6, richard2024exploringrnatherapeutics pages 1-2)

  5. Key statistics and recent data highlights (mechanistically relevant)

Epidemiology - From 2024 review: “Global birth prevalence of ARG1-D: 2.8 cases/1,000,000 live births” and “Population prevalence of ARG1-D: 1.4 cases/1,000,000 people.” (nteli2024argininemiapathophysiologyand pages 8-10) - The same review reports a median prevalence estimate of ~1:1,000,000 births (with wide study ranges). (nteli2024argininemiapathophysiologyand pages 1-2)

Natural history / phenotype frequencies - Upper motor neuron involvement ~80%. (nteli2024argininemiapathophysiologyand pages 2-3) - Seizures ~60–75%. (nteli2024argininemiapathophysiologyand pages 2-3)

Biomarkers - Plasma arginine can exceed 300 µmol/L and therapeutic target is <200 µmol/L. (nteli2024argininemiapathophysiologyand pages 5-7) - NBS support: Arg/Orn ratio ≥1.4 identified all arginase cases in the cited study; arginine alone may be near-normal in newborns due to maternal arginase or ARG2. (nteli2024argininemiapathophysiologyand pages 7-8, nteli2024argininemiapathophysiologyand pages 5-7)

Therapy effect size (phase 3) - PEACE trial: pArg reduction 354.0 → 86.4 µmol/L at Week 24; normalization 90.5% vs 0%. (russo2024efficacyandsafety pages 1-2) - Visual support for these endpoints is available in extracted Figure/Table region. (russo2024efficacyandsafety media be435973, russo2024efficacyandsafety media f9206652)

  1. Knowledge-base ready annotation tables (ontology-oriented)

12.1 Gene/protein - ARG1 (HGNC symbol: ARG1; protein: arginase 1). Evidence: causal biallelic variants; enzymatic role in urea cycle. (russo2024efficacyandsafety pages 1-2, nteli2024argininemiapathophysiologyand pages 2-3)

12.2 Candidate GO process annotations (evidence-motivated) - Nitrogen compound metabolic process / urea cycle / ureagenesis (ARG1 function loss). (nteli2024argininemiapathophysiologyand pages 2-3) - Arginine catabolic process (ARG1 catalytic lesion). (nteli2024argininemiapathophysiologyand pages 2-3) - Myelination / CNS development (dysmyelination; therapy-associated myelination rescue in mice). (nteli2024argininemiapathophysiologyand pages 3-5, richard2024exploringrnatherapeutics pages 4-6) - Response to oxidative stress (arginine excess; GC-linked oxidative stress). (nteli2024argininemiapathophysiologyand pages 3-5, nteli2024argininemiapathophysiologyand pages 12-14)

12.3 Phenotypes (HP term suggestions; evidence-backed concept level) - Spasticity / spastic paraplegia phenotype (progressive spastic diplegia/paraparesis). (nteli2024argininemiapathophysiologyand pages 2-3) - Seizures. (nteli2024argininemiapathophysiologyand pages 2-3) - Developmental delay / intellectual disability. (nteli2024argininemiapathophysiologyand pages 1-2) - Liver dysfunction / hepatic pathology. (nteli2024argininemiapathophysiologyand pages 1-2)

12.4 Cell types (CL term suggestions; evidence-backed concept level) - Hepatocyte; neuron; oligodendrocyte; erythrocyte; macrophage lineage (ARG1 expression noted). (nteli2024argininemiapathophysiologyand pages 2-3, russo2024efficacyandsafety pages 16-16, nteli2024argininemiapathophysiologyand pages 3-5)

12.5 Anatomy (UBERON term suggestions; evidence-backed concept level) - Liver; brain/CNS; CSF. (nteli2024argininemiapathophysiologyand pages 2-3, nteli2024argininemiapathophysiologyand pages 12-14)

  1. Evidence items (PMID-focused)

Important limitation: The 2024 full-text excerpts retrieved here provide strong mechanistic synthesis and clinical trial results, but they do not reproduce all underlying primary-study PMIDs inline in the extracted snippets. Where the excerpt explicitly references primary literature by concept but not PMID, the evidence is still attributable to the 2024 peer-reviewed sources above.

Primary 2024 anchor papers (with DOI/URL and publication month/year) - Nteli D et al. “Argininemia: Pathophysiology and Novel Methods for Evaluation of the Disease.” Applied Sciences. Feb 2024. DOI: 10.3390/app14041647. URL: https://doi.org/10.3390/app14041647. (nteli2024argininemiapathophysiologyand pages 1-2) - Russo RS et al. “Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3…” eClinicalMedicine. Feb 2024. DOI: 10.1016/j.eclinm.2023.102405. URL: https://doi.org/10.1016/j.eclinm.2023.102405. (russo2024efficacyandsafety pages 1-2) - Duff C et al. “Gene therapy for urea cycle defects: An update…” J Inherit Metab Dis. Apr 2024. DOI: 10.1002/jimd.12609. URL: https://doi.org/10.1002/jimd.12609. (duff2024genetherapyfor pages 11-12) - Richard E et al. “Exploring RNA therapeutics for urea cycle disorders.” J Inherit Metab Dis. Oct 2024. DOI: 10.1002/jimd.12807. URL: https://doi.org/10.1002/jimd.12807. (richard2024exploringrnatherapeutics pages 4-6)

Clinical trial registry evidence (URLs) - NCT03921541. https://clinicaltrials.gov/study/NCT03921541. (NCT03921541 chunk 3) - NCT02488044. https://clinicaltrials.gov/study/NCT02488044. (NCT02488044 chunk 1) - NCT03378531. https://clinicaltrials.gov/study/NCT03378531. (NCT03378531 chunk 1) - NCT06582524. https://clinicaltrials.gov/study/NCT06582524. (NCT06582524 chunk 1)

Appendix: Direct quotes captured (for knowledge-base curation) - “hydrolysis of L-arginine to ornithine and urea.” (ARG1 function) (nteli2024argininemiapathophysiologyand pages 2-3) - “Arginine: the key driver of patophysiology and progression in arginase 1 deficiency” (disease driver framing) (russo2024efficacyandsafety pages 16-16) - “as high as four times the normal (>300 µmol/L)” and “reduce arginine concentration in plasma below 200 µmol/L” (biomarker magnitude and target) (nteli2024argininemiapathophysiologyand pages 5-7) - “codon-optimized ARG1 mRNA encapsulated in LNPs led to 100% survival of arginase-deficient mice…” and “intermittent administration of LNPs carrying ARG1 mRNA significantly improved myelination…” (preclinical RNA-therapy efficacy) (richard2024exploringrnatherapeutics pages 4-6)

End of report.

References

  1. (russo2024efficacyandsafety pages 1-2): Rossana Sanchez Russo, Serena Gasperini, Gillian Bubb, Linda Neuman, Leslie S. Sloan, George A. Diaz, and Gregory M. Enns. Efficacy and safety of pegzilarginase in arginase 1 deficiency (peace): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial. eClinicalMedicine, 68:102405, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2023.102405, doi:10.1016/j.eclinm.2023.102405. This article has 21 citations and is from a peer-reviewed journal.

  2. (nteli2024argininemiapathophysiologyand pages 2-3): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 3 citations.

  3. (nteli2024argininemiapathophysiologyand pages 7-8): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 3 citations.

  4. (nteli2024argininemiapathophysiologyand pages 3-5): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 3 citations.

  5. (russo2024efficacyandsafety pages 16-16): Rossana Sanchez Russo, Serena Gasperini, Gillian Bubb, Linda Neuman, Leslie S. Sloan, George A. Diaz, and Gregory M. Enns. Efficacy and safety of pegzilarginase in arginase 1 deficiency (peace): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial. eClinicalMedicine, 68:102405, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2023.102405, doi:10.1016/j.eclinm.2023.102405. This article has 21 citations and is from a peer-reviewed journal.

  6. (nteli2024argininemiapathophysiologyand pages 5-7): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 3 citations.

  7. (nteli2024argininemiapathophysiologyand pages 1-2): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 3 citations.

  8. (nteli2024argininemiapathophysiologyand pages 12-14): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 3 citations.

  9. (richard2024exploringrnatherapeutics pages 4-6): Eva Richard, Ainhoa Martínez‐Pizarro, and Lourdes R. Desviat. Exploring rna therapeutics for urea cycle disorders. Journal of Inherited Metabolic Disease, 47:1269-1277, Oct 2024. URL: https://doi.org/10.1002/jimd.12807, doi:10.1002/jimd.12807. This article has 4 citations and is from a peer-reviewed journal.

  10. (russo2024efficacyandsafety pages 15-16): Rossana Sanchez Russo, Serena Gasperini, Gillian Bubb, Linda Neuman, Leslie S. Sloan, George A. Diaz, and Gregory M. Enns. Efficacy and safety of pegzilarginase in arginase 1 deficiency (peace): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial. eClinicalMedicine, 68:102405, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2023.102405, doi:10.1016/j.eclinm.2023.102405. This article has 21 citations and is from a peer-reviewed journal.

  11. (russo2024efficacyandsafety media be435973): Rossana Sanchez Russo, Serena Gasperini, Gillian Bubb, Linda Neuman, Leslie S. Sloan, George A. Diaz, and Gregory M. Enns. Efficacy and safety of pegzilarginase in arginase 1 deficiency (peace): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial. eClinicalMedicine, 68:102405, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2023.102405, doi:10.1016/j.eclinm.2023.102405. This article has 21 citations and is from a peer-reviewed journal.

  12. (russo2024efficacyandsafety media f9206652): Rossana Sanchez Russo, Serena Gasperini, Gillian Bubb, Linda Neuman, Leslie S. Sloan, George A. Diaz, and Gregory M. Enns. Efficacy and safety of pegzilarginase in arginase 1 deficiency (peace): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial. eClinicalMedicine, 68:102405, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2023.102405, doi:10.1016/j.eclinm.2023.102405. This article has 21 citations and is from a peer-reviewed journal.

  13. (duff2024genetherapyfor pages 11-12): Claire Duff, Ian E. Alexander, and Julien Baruteau. Gene therapy for urea cycle defects: an update from historical perspectives to future prospects. Journal of Inherited Metabolic Disease, 47:50-62, Apr 2024. URL: https://doi.org/10.1002/jimd.12609, doi:10.1002/jimd.12609. This article has 28 citations and is from a peer-reviewed journal.

  14. (russo2024efficacyandsafety pages 2-3): Rossana Sanchez Russo, Serena Gasperini, Gillian Bubb, Linda Neuman, Leslie S. Sloan, George A. Diaz, and Gregory M. Enns. Efficacy and safety of pegzilarginase in arginase 1 deficiency (peace): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial. eClinicalMedicine, 68:102405, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2023.102405, doi:10.1016/j.eclinm.2023.102405. This article has 21 citations and is from a peer-reviewed journal.

  15. (NCT03921541 chunk 3): Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency. Aeglea Biotherapeutics. 2019. ClinicalTrials.gov Identifier: NCT03921541

  16. (NCT02488044 chunk 1): A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency. Aeglea Biotherapeutics. 2016. ClinicalTrials.gov Identifier: NCT02488044

  17. (NCT03378531 chunk 1): A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency. Aeglea Biotherapeutics. 2017. ClinicalTrials.gov Identifier: NCT03378531

  18. (NCT06582524 chunk 1): Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency. Immedica Pharma AB. 2024. ClinicalTrials.gov Identifier: NCT06582524

  19. (russo2024efficacyandsafety pages 13-14): Rossana Sanchez Russo, Serena Gasperini, Gillian Bubb, Linda Neuman, Leslie S. Sloan, George A. Diaz, and Gregory M. Enns. Efficacy and safety of pegzilarginase in arginase 1 deficiency (peace): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial. eClinicalMedicine, 68:102405, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2023.102405, doi:10.1016/j.eclinm.2023.102405. This article has 21 citations and is from a peer-reviewed journal.

  20. (richard2024exploringrnatherapeutics pages 1-2): Eva Richard, Ainhoa Martínez‐Pizarro, and Lourdes R. Desviat. Exploring rna therapeutics for urea cycle disorders. Journal of Inherited Metabolic Disease, 47:1269-1277, Oct 2024. URL: https://doi.org/10.1002/jimd.12807, doi:10.1002/jimd.12807. This article has 4 citations and is from a peer-reviewed journal.

  21. (nteli2024argininemiapathophysiologyand pages 8-10): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 3 citations.

OpenScientist ▸
1. Disease Information
openscientist-autonomous 35 citations 2026-05-05T07:20:40.927992

1. Disease Information

Overview

Arginase 1 deficiency (ARG1-D), also known as hyperargininemia or argininemia, is an ultra-rare autosomal recessive inherited metabolic disorder of the urea cycle. It results from partial or complete loss of arginase 1 (ARG1) enzyme activity, which catalyzes the final step of the urea cycle: the hydrolysis of L-arginine to L-ornithine and urea. The disease is characterized by chronic elevation of plasma arginine (hyperargininemia) and a distinct, progressive neurological phenotype that differentiates it from all other urea cycle disorders (PMID: 41651652; PMID: 36175366).

As stated in the literature: "Arginase 1 deficiency (ARG1-D) is an ultra-rare inherited metabolic disorder of the urea cycle, caused by partial or complete loss of arginase 1 function, characterised by hyperargininaemia and a distinct, progressive neurological phenotype" (PMID: 41651652).

Key Identifiers

Identifier Value
OMIM (Disease) 207800 (Argininemia)
OMIM (Gene) 608313 (ARG1)
MONDO MONDO:0009033
Orphanet ORPHA:14
ICD-10 E72.21 (Argininemia)
ICD-11 5C50.13 (Arginase deficiency)
MeSH D020162 (Hyperargininemia)
GARD 2854

Synonyms and Alternative Names

  • Hyperargininemia
  • Argininemia
  • Arginase deficiency
  • ARG1 deficiency (ARG1-D)
  • Arginase 1 deficiency
  • Urea cycle disorder – arginase type

Information Sources

This report synthesizes information from aggregated disease-level resources including OMIM, Orphanet, GeneReviews, ClinVar, and published literature (systematic reviews, natural history studies, clinical trial data). Key data sources include a systematic review of 157 published case reports (PMID: 35822089), the largest prospective clinical cohort (n=48) from pegzilarginase trials (PMID: 41651652), and epidemiological systematic reviews (PMID: 36049366).

2. Etiology

Disease Causal Factors

ARG1-D is a purely genetic disease caused by biallelic (homozygous or compound heterozygous) pathogenic variants in the ARG1 gene. There are no environmental, infectious, or multifactorial components to disease causation. The genetic defect leads to loss of arginase 1 enzyme function, resulting in accumulation of arginine and its metabolites.

"This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea" (PMID: 26467175).

Genetic Risk Factors

  • Causal variants: Over 40 distinct pathogenic mutations have been identified in the ARG1 gene, with 183 pathogenic/likely pathogenic variants listed in ClinVar. Variants include missense, nonsense, frameshift, splice-site mutations, and large deletions/duplications.
  • Consanguinity: As an autosomal recessive disorder, consanguinity significantly increases the risk of affected offspring. Several case reports highlight consanguineous families (PMID: 38584907).
  • Founder effects: A cluster of ARG1-D in the Comoros Islands (Mayotte) has been identified, associated with two severe founder variants (c.466-2A>G and c.766G>A) found exclusively in individuals of Comorian origin (PMID: 41684183).

Environmental Risk Factors (Modifiers of Severity)

While no environmental factors cause the disease, several environmental triggers can precipitate acute metabolic decompensation in affected individuals: - High-protein diet: Excessive protein intake increases arginine load and can worsen hyperargininemia - Intercurrent illness/infection: Catabolic states can trigger secondary hyperammonemia - Certain medications: Valproate (valproic acid) can provoke hyperammonemic crises and should be avoided (PMID: 37243436)

Protective Factors

  • Early diagnosis and treatment: Early initiation of protein restriction and arginine-lowering therapy correlates with better neurological outcomes. Newborn screening identification with treatment started at 21 days resulted in unremarkable development at 18 months (PMID: 21229317).
  • Residual enzyme activity: Some mutations allow partial enzyme function, which may be associated with milder phenotypes, though clear genotype-phenotype correlations are lacking.

Gene-Environment Interactions

The primary gene-environment interaction in ARG1-D involves dietary protein: the degree of dietary arginine intake directly modulates the severity of hyperargininemia. During intercurrent illness, protein catabolism releases endogenous amino acids, overwhelming the impaired urea cycle. Valproate sensitivity has been documented, where this antiepileptic drug can exacerbate hyperammonemia in unrecognized ARG1-D patients (PMID: 37243436).

3. Phenotypes

Core Phenotypic Features

The phenotype of ARG1-D is dominated by progressive neurological manifestations. The following table summarizes key phenotypes with their frequencies, HPO terms, and characteristics:

Phenotype HPO Term Frequency Onset Severity Progression
Motor impairment HP:0001270 (Motor delay) 100% Childhood (2-4 yr) Moderate-severe Progressive
Spasticity (lower limbs) HP:0001258 (Spastic paraplegia) 69% Childhood Moderate-severe Progressive
Cognitive deficits HP:0100543 (Cognitive impairment) 65% Childhood Variable Progressive
Intellectual disability HP:0001249 (Intellectual disability) 64% Childhood Mild-severe Progressive
Speech/language deficits HP:0002167 (Neurological speech impairment) 54% Childhood Variable Progressive
Seizures HP:0001250 (Seizures) 38% Variable Variable Episodic
Hyperargininemia HP:0003645 (Elevated plasma arginine) ~100% Neonatal/infancy Variable Chronic
Growth retardation HP:0001510 (Growth delay) Common Childhood Variable Chronic
Microcephaly HP:0000252 (Microcephaly) Occasional Childhood Variable Stable
Hepatomegaly HP:0002240 (Hepatomegaly) Occasional Variable Variable Variable
Neonatal cholestasis HP:0006566 (Neonatal cholestasis) Rare Neonatal Variable May resolve

Frequencies derived from the largest prospective cohort (n=48): "Clinical features included motor impairment (48/48, 100%), spasticity (33/48, 69%), cognitive deficits (31/48, 65%), intellectual disability (23/36, 64%), speech and language deficits (26/48, 54%), and seizures (18/48, 38%)" (PMID: 41651652).

Laboratory Abnormalities

Laboratory Finding HPO Term Frequency Details
Elevated plasma arginine HP:0003645 ~100% Typically >200 μmol/L (often >350 μmol/L); normal <115 μmol/L
Elevated guanidino compounds HP:0003355 (Aminoaciduria) ~100% Guanidinoacetate, argininic acid in urine
Hyperammonemia HP:0001987 (Hyperammonemia) Variable (~30%) Comparatively less severe than other UCDs
Elevated orotic acid — Common Secondary to urea cycle dysfunction
Reduced arginase activity in RBCs — ~100% Diagnostic confirmation

Epilepsy Spectrum

Seizure semiology in ARG1-D is diverse. Cases consistent with Lennox-Gastaut syndrome and developmental epileptic encephalopathy have been reported (PMID: 37243436). Status epilepticus has been documented as a presenting feature (PMID: 36474391).

Quality of Life Impact

ARG1-D imposes a severe burden on quality of life. A claims database study demonstrated that patients with ARG1-D have: emergency room visits twice as frequent, hospitalizations 3 times more common, and mean length of stay 8 times longer (2.4 vs. 0.3 days) compared to matched controls (PMID: 35695271). "Patients with ARG1-D had significantly greater HCRU compared with those without the disease; they presented with a more extensive comorbidity profile, accessed the health care system more frequently, required more intense monitoring and management" (PMID: 35695271).

4. Genetic/Molecular Information

Causal Gene

Property Detail
Gene Symbol ARG1
HGNC ID HGNC:663
NCBI Gene ID 383
OMIM Gene 608313
Chromosome Location 6q23.2
Protein Arginase-1 (UniProt P05089)
Protein Length 330 amino acids (mature: 322 aa)
Gene Structure 8 exons
Enzyme Commission EC 3.5.3.1

Protein Structure and Function

Arginase 1 is a homotrimeric binuclear manganese metalloenzyme. Each subunit contains a binuclear Mn²⁺ cluster essential for catalytic activity. The enzyme catalyzes the hydrolysis of L-arginine to produce L-ornithine and urea, the terminal step of the urea cycle.

The crystal structure of human arginase I has been extensively characterized, revealing that the active site contains two Mn²⁺ ions coordinated by His101, Asp124, Asp128, Asp232, Asp234, and His141 (PMID: 23327293).

Pathogenic Variants

ClinVar lists 183 pathogenic/likely pathogenic variants in ARG1, including:

Variant Type Frequency Examples
Missense Most common p.R21C, p.G235R, p.T134I, p.L216P
Nonsense Common p.R308, p.W122
Frameshift Common c.263-266delAGAA (p.K88Rfs*45)
Splice-site Common c.466-2A>G, IVS4-2A>G
Large deletions Rare Whole exon deletions
Synonymous (splicing) Rare c.57G>A (p.Q19=) — affects splicing

Mutations are distributed fairly uniformly throughout the gene: "This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene" (PMID: 26467175).

Bioinformatics analyses of missense mutations revealed three mechanisms of protein dysfunction: "missense mutations (1) affect the ARG1 active site, (2) interfere with the stability of the ARG1 folded conformation or (3) alter the quaternary structure of the ARG1" (PMID: 22959135).

Notable Variant: c.57G>A

A synonymous variant (c.57G>A, p.Q19=) has been shown to affect alternative splicing, leading to exon 2 deletion (73 bp) and activation of nonsense-mediated mRNA decay. This variant has a relatively high minor allele frequency (MAF = 0.0146) in the general population and possesses partial pathogenic potential (PMID: 39567422).

Functional Consequences

All pathogenic variants result in loss of function of arginase 1. The disorder is never caused by gain-of-function or dominant-negative mechanisms. Variants are germline in origin (never somatic). The functional consequence is reduced or absent hydrolysis of arginine, leading to arginine accumulation and impaired ureagenesis.

Genotype-Phenotype Correlation

No clear genotype-phenotype correlation has been established. Patients with identical mutations can have variable clinical outcomes, likely influenced by: - Residual enzyme activity - Dietary and environmental factors - Modifier genes (not yet identified) - Timing of diagnosis and treatment initiation

Epigenetic and Chromosomal Information

No specific epigenetic modifications or chromosomal abnormalities beyond point mutations and small indels have been reported as causative. No modifier genes have been definitively identified, though variability in clinical expression suggests their existence.

5. Environmental Information

Environmental Factors

ARG1-D is a purely genetic disorder; no environmental agents cause the disease. However, environmental factors modulate disease expression:

  • Dietary protein: The most critical environmental modifier. Protein intake directly affects arginine load and disease severity.
  • Intercurrent illness: Infections, surgery, and other catabolic stresses can precipitate hyperammonemic crises.
  • No occupational, toxic, or radiation-related factors are implicated.

Lifestyle Factors

  • Diet: Protein-restricted diet is the cornerstone of management. Excessive protein intake worsens hyperargininemia.
  • Exercise: Heavy exercise can trigger metabolic decompensation in UCDs (PMID: 40285952).

Infectious Agents

No infectious agents cause ARG1-D. However, infections serve as metabolic stressors that can precipitate acute decompensation.

6. Mechanism / Pathophysiology

Molecular Pathways

The core biochemical defect involves the urea cycle (KEGG: hsa00220), specifically the terminal reaction:

L-Arginine + H₂O → L-Ornithine + Urea
    ↑
      Arginase 1 (ARG1)
      [DEFICIENT in ARG1-D]

Upstream pathway disruption:

NH₃ + CO₂ + ATP → Carbamoyl phosphate (CPS1)
         ↓
Ornithine + Carbamoyl phosphate → Citrulline (OTC)
                       ↓
Citrulline + Aspartate → Argininosuccinate (ASS1)
                ↓
Argininosuccinate → Fumarate + Arginine (ASL)
                    ↓
Arginine → Ornithine + Urea (ARG1) ← BLOCKED

When ARG1 is deficient, arginine accumulates and ornithine production is reduced. The ornithine deficiency impairs the cycle's ability to regenerate its starting substrate, but the cycle is not completely blocked because arginase 2 (mitochondrial isoform) provides partial compensation.

Key pathway identifiers: - KEGG: hsa00220 (Urea cycle) - Reactome: R-HSA-70635 (Urea cycle) - GO:0000050 (urea cycle) - GO:0006525 (arginine metabolic process)

Causal Chain from Genetic Defect to Clinical Manifestations

ARG1 mutations (germline, biallelic)
↓
Loss of arginase 1 enzyme activity
↓
    ┌───────────────────┬──────────────────┐
    ↓                   ↓                  ↓
Hyperargininemia    Decreased ornithine  Mild ↑ ammonia
(PRIMARY driver)    (impaired cycle      (SECONDARY; less
     regeneration)       severe than other UCDs)
    ↓                                      ↓
Accumulation of                        Occasional
guanidino compounds                    hyperammonemic
(GAA, γ-GBA, GES)                     episodes
    ↓
Neurotoxicity via:
• GABA_A receptor agonism by GAA
• Nitric oxide pathway dysregulation
• Oxidative stress
• White matter damage
    ↓
Progressive neurological phenotype:
- Spastic diplegia/paraplegia
- Intellectual disability
- Seizures
- Loss of ambulation

Hyperargininemia as the Primary Pathogenic Mechanism

A critical distinction from other UCDs: "Unlike the typical presentation of other urea cycle disorders, individuals with ARG1-D usually appear healthy at birth and hyperammonemia is comparatively less severe and less common. Clinical manifestations typically begin to develop in early childhood in association with high plasma arginine levels, with hyperargininemia (and not hyperammonemia) considered to be the primary driver of disease sequelae" (PMID: 36175366).

Guanidino Compound Neurotoxicity

Accumulation of guanidino compounds derived from arginine—including guanidinoacetate (GAA), γ-guanidinobutyric acid (γ-GBA), and guanidinoethanesulfonic acid (GES)—contributes to neurological damage. These compounds share structural similarity with GABA and act as GABA_A receptor agonists, potentially disrupting inhibitory neurotransmission (PMID: 36726215).

GO terms for biological processes: - GO:0000050 — urea cycle - GO:0006525 — arginine metabolic process - GO:0006527 — arginine catabolic process - GO:0042401 — biogenic amine biosynthetic process - GO:0007268 — chemical synaptic transmission

Protein Dysfunction

Pathogenic variants affect arginase 1 through three mechanisms (PMID: 22959135): 1. Active site disruption: Mutations directly affecting residues involved in manganese coordination or substrate binding 2. Protein destabilization: Mutations interfering with the stability of the folded monomer conformation 3. Quaternary structure alteration: Mutations disrupting the homotrimeric assembly required for full enzyme activity

Metabolic Changes (CHEBI terms)

Metabolite CHEBI Change Significance
L-Arginine CHEBI:16467 ↑↑↑ Primary biomarker; neurotoxic
L-Ornithine CHEBI:15729 ↓ Reduced product of blocked reaction
Urea CHEBI:16199 ↓ Reduced product
Guanidinoacetate CHEBI:16344 ↑ Neurotoxic; GABA_A agonist
Ammonia CHEBI:16134 ↑ (mild) Secondary; less severe than other UCDs
Orotic acid CHEBI:16742 ↑ Secondary to urea cycle dysfunction

Cortical Circuit Dysfunction

Studies in murine models demonstrated that loss of arginase 1 expression results in decreased dendritic complexity, decreased excitatory and inhibitory synapse numbers, decreased intrinsic excitability, and altered synaptic transmission in layer 5 motor cortical neurons (PMID: 27335400). These findings provide a direct link between the metabolic defect and motor cortical dysfunction underlying spasticity.

Immune System Involvement

ARG1-D is not primarily an immune-mediated disorder. However, arginase 1 plays roles in immune regulation (arginine is the substrate for nitric oxide synthase in macrophages), and its systemic deficiency may have immunological consequences that are not yet fully characterized.

Neuroimaging Correlates

Brain MRI findings include: - White matter abnormalities (multicystic white matter lesions in severe cases) (PMID: 20456883) - Cerebral and cerebellar atrophy - Bilateral posterior putamen and insular cortex infarction - MR spectroscopy shows elevated choline/creatine ratios and an abnormal peak at 3.8 ppm, likely representing arginine deposition (PMID: 18321250)

7. Anatomical Structures Affected

Organ Level

Organ/System Level UBERON/Description
Brain Primary UBERON:0000955 — Main target of arginine/guanidino toxicity
Liver Primary UBERON:0002107 — Site of arginase 1 expression; occasional hepatic involvement
Spinal cord Primary UBERON:0002240 — Corticospinal tract involvement (spasticity)
Skeletal muscle Secondary UBERON:0001134 — Spasticity-related complications
Nervous system Primary UBERON:0001016 — Central and peripheral

Body systems involved: - Nervous system (primary): Progressive spasticity, intellectual disability, seizures - Hepatic system (variable): Occasional hepatomegaly, neonatal cholestasis, rare liver failure - Musculoskeletal system (secondary): Contractures from chronic spasticity

Tissue and Cell Level

Tissue/Cell Type Cell Ontology Involvement
Hepatocytes CL:0000182 Primary site of ARG1 expression; enzyme deficiency
Cortical neurons (Layer 5) CL:0000679 Decreased dendritic complexity, synaptic loss
Upper motor neurons CL:0000540 Corticospinal tract dysfunction → spasticity
Red blood cells CL:0000232 Express ARG1; used for diagnostic enzyme assay
White matter (oligodendrocytes) CL:0000128 Demyelination/dysmyelination

Subcellular Level

Compartment GO Term Relevance
Cytoplasm GO:0005737 Arginase 1 is a cytoplasmic enzyme in hepatocytes
Mitochondria GO:0005739 Arginase 2 (compensatory isoform) is mitochondrial
Synapse GO:0045202 Synaptic dysfunction in motor cortex

Localization

  • Brain regions: Motor cortex (UBERON:0001384), white matter tracts (UBERON:0002316), basal ganglia/putamen (UBERON:0001874), cerebellum (UBERON:0002037)
  • Spinal cord: Corticospinal tract (UBERON:0002712)
  • Liver: Hepatic parenchyma (UBERON:0001280)
  • Lateralization: Bilateral and symmetric (spastic diplegia)

8. Temporal Development

Onset

  • Typical age of onset: Early childhood (2–4 years); mean onset 2.2 years (SD 3.6) from the largest cohort (PMID: 41651652)
  • Onset pattern: Insidious and progressive
  • Neonatal presentation: Very rare; when present, may manifest as neonatal cholestasis or hyperammonemic encephalopathy (PMID: 21229317; PMID: 19381865)
  • Adult-onset/late presentation: Rare but documented; a 23-year-old case presented with progressive spasticity (PMID: 38584907)

Progression

Stage Features Typical Age
Pre-symptomatic Elevated arginine on NBS; normal development 0–2 years
Early Developmental delay, gait abnormalities, growth failure 2–5 years
Intermediate Progressive spasticity, seizure onset, cognitive decline 5–15 years
Advanced Loss of ambulation, severe intellectual disability, refractory seizures Adolescence–adulthood
  • Progression rate: Slowly progressive; "symptom-onset data consistent with a progressive phenotype" (PMID: 41651652)
  • Disease course: Chronic, progressive, lifelong
  • Duration: Lifelong without cure; life expectancy may be near-normal with treatment, but quality of life significantly impaired

Critical Periods

  • Neonatal period: Window for newborn screening identification and early intervention
  • Early childhood (0–4 years): Critical window before irreversible neurological damage accumulates
  • Early treatment initiation: Associated with dramatically better outcomes (case comparison: NBS-identified infant with normal development at 18 months vs. delayed-diagnosis infant with progressive liver failure) (PMID: 21229317)

9. Inheritance and Population

Epidemiology

Metric Value Source
Prevalence ~1 in 1,000,000 Systematic review of 10 studies (PMID: 36049366)
Global birth prevalence 2.8 per million live births gnomAD-derived estimate (PMID: 35236361)
Country-specific range 0.92–17.5 per million live births (PMID: 35236361)
Population prevalence ~1.4 per million (~1/726,000) (PMID: 35236361)

"Global birth prevalence for ARG1-D was estimated at 2.8 cases per million live births (country-specific estimates ranged from 0.92 to 17.5) and population prevalence to be 1.4 cases per million people (approximately 1/726,000 people)" (PMID: 35236361).

Genetic Features

Feature Detail
Inheritance pattern Autosomal recessive (AR)
Penetrance Complete (all biallelic pathogenic variant carriers develop disease)
Expressivity Variable (severity varies even with same genotype)
Genetic anticipation Not applicable
Germline mosaicism Not reported
Carrier frequency Estimated at ~1/500 based on gnomAD allele frequencies

Founder Effects

  • Comoros Islands/Mayotte: Two severe variants (c.466-2A>G and c.766G>A) found exclusively in individuals of Comorian origin, leading to a regional cluster (PMID: 41684183)
  • Bulgaria: A potential endemic region identified with multiple cases (PMID: 36722221)

Population Demographics

  • Sex ratio: Approximately equal (52% male in claims database study; PMID: 35695271)
  • Ethnic distribution: Reported across all ethnic groups worldwide; no specific ethnic predilection, though founder effects exist in certain populations
  • Age distribution: Median age 15 years in claims data; 52% under 18 years (PMID: 35695271)
  • Consanguinity: Increased risk in consanguineous populations

10. Diagnostics

Clinical Tests

Laboratory Tests

Test Specimen Finding Diagnostic Utility
Plasma amino acid analysis (PAAA) Blood Elevated arginine (>200 μmol/L, often >350) Primary screening/diagnostic
Urine amino acid analysis Urine Elevated arginine, orotic acid, guanidino compounds Supportive
Erythrocyte arginase activity RBCs Reduced/absent enzyme activity Confirmatory (gold standard pre-genetics)
Plasma ammonia Blood Normal to mildly elevated Variable; less diagnostic than in other UCDs
Urine orotic acid Urine Elevated Supportive

Key ratios for newborn screening: - Arginine/ornithine ratio >1.4 improves screening specificity - Arginine cutoff of 50 μmol/L combined with Arg/Orn ratio of 1.4 yields recall rate of 0.01% (PMID: 28659245)

Biomarkers

Biomarker CHEBI Use
Plasma arginine CHEBI:16467 Primary diagnostic and monitoring biomarker
Guanidinoacetate (GAA) CHEBI:16344 Marker of arginine metabolite accumulation
Plasma ammonia CHEBI:16134 Monitoring for hyperammonemic crises

Imaging

  • Brain MRI: White matter abnormalities, cerebral/cerebellar atrophy, bilateral putamen/insular cortex lesions (PMID: 18321250; PMID: 20456883)
  • MR Spectroscopy: Elevated choline/creatine ratios; abnormal peak at 3.8 ppm (arginine) (PMID: 18321250)

Electrophysiology

  • EEG: Abnormal in patients with seizures; patterns consistent with Lennox-Gastaut syndrome or developmental epileptic encephalopathy reported (PMID: 37243436)

Genetic Testing

Method Utility Recommendation
Single gene testing (ARG1) High First-line when biochemical profile is suggestive
Gene panels (UCD panels, metabolic panels) High Recommended when UCD suspected but type unclear
Whole exome sequencing (WES) High When panels are negative or presentation atypical
Whole genome sequencing (WGS) Moderate May detect structural variants missed by WES
Chromosomal microarray Low Not typically informative for ARG1-D

ARG1 should be included in hereditary spastic paraplegia gene panels to avoid misdiagnosis (PMID: 36698992).

Screening

  • Newborn screening: ARG1-D is a secondary target on the U.S. Recommended Uniform Screening Panel (RUSP). Tandem mass spectrometry (MS/MS) of dried blood spots detects elevated arginine. Implementation of arginine/ornithine ratios improves specificity (PMID: 28659245).
  • Carrier screening: Not part of routine carrier screening panels
  • Cascade screening: Recommended for siblings and family members of affected individuals

Differential Diagnosis

Condition Distinguishing Features
Hereditary spastic paraplegia (HSP) Normal plasma arginine; genetic testing for HSP genes
Cerebral palsy Non-progressive (vs. progressive in ARG1-D); normal metabolic screening
HHH syndrome Elevated ornithine (not arginine); homocitrullinuria
Other urea cycle disorders Different amino acid profiles; typically more severe hyperammonemia
Developmental epileptic encephalopathy Metabolic screening differentiates

"Arginase 1 Deficiency should be considered in HSP differential diagnosis until biochemically/genetically excluded" (PMID: 36698992).

11. Outcome/Prognosis

Survival and Mortality

  • Life expectancy: Variable; many patients survive into adulthood, unlike severe proximal UCDs. Death is less common than in other UCDs (PMID: 26467175).
  • Mortality: In a Mexican cohort, UCD mortality was 38% for symptomatic patients overall, but neonatal-onset disease had higher mortality (PMID: 20025860). ARG1-D specifically has lower mortality than proximal UCDs.
  • Early-onset severe forms: Neonatal presentation with liver failure and prolonged hyperammonemia can be lethal or result in severe disability (PMID: 19381865).

Morbidity and Function

  • Progressive disability: Without treatment, most patients develop progressive loss of ambulation, severe intellectual disability, and refractory epilepsy
  • Healthcare utilization: Significantly elevated—3× more hospitalizations, 2× more ER visits, and 8× longer hospital stays compared to matched controls (PMID: 35695271)

Prognostic Factors

Factor Better Prognosis Worse Prognosis
Age at diagnosis Early (NBS) Late (>6 years)
Treatment initiation Early Delayed
Residual enzyme activity Present Absent
Diagnostic delay Short Long
Access to specialized care Good Limited

The Mayotte vs. Paris comparison demonstrated that "despite no significant differences in laboratory parameters, clinical outcomes remained better in NEM [Paris] versus CHM [Mayotte] possibly ascribable to a longer diagnostic delay in CHM" (PMID: 41684183).

Complications

  • Progressive spastic quadriparesis and loss of ambulation
  • Refractory epilepsy
  • Severe intellectual disability
  • Growth failure
  • Contractures and orthopedic complications
  • Rare: liver failure, rhabdomyolysis (PMID: 38584907)

12. Treatment

Pharmacotherapy

Pegzilarginase (Enzyme Replacement Therapy)

Pegzilarginase is a PEGylated recombinant human arginase 1 enzyme that represents the first disease-modifying therapy for ARG1-D.

Phase 3 PEACE Trial (NCT03921541): "Pegzilarginase lowered geometric mean pArg from 354.0 μmol/L to 86.4 μmol/L at Week 24 vs 464.7 to 426.6 μmol/L for placebo" (PMID: 38292042) — representing a ~75% reduction in plasma arginine.

Long-term Extension Studies: "Of 39 evaluable participants, 37 (95%) met composite response or achieved maximum score in ≥ 1 motor function domain" (PMID: 40714964). Spasticity improved in 21/25 (84%) patients, with 12 reaching MAS 0. 6-minute walk test improved by +19% (68.2 m) over up to 5 years.

MAXO term: MAXO:0001298 (enzyme replacement therapy)

Nitrogen Scavengers

Drug Mechanism MAXO Term
Sodium benzoate Conjugates glycine → hippurate MAXO:0000127
Sodium/glycerol phenylbutyrate Conjugates glutamine → phenylacetylglutamine MAXO:0000127

"Pharmacological scavengers of nitrogen are benzoate and butyrate" (PMID: 40285952)

Antiepileptic Drugs

  • Seizure management with appropriate anticonvulsants
  • Important: Valproate should be avoided due to risk of precipitating hyperammonemia (PMID: 37243436)
  • MAXO term: MAXO:0000950 (anticonvulsant therapy)

Antispasticity Agents

  • Baclofen (oral and intrathecal)
  • Botulinum toxin injections
  • Eperisone hydrochloride
  • MAXO term: MAXO:0010033 (antispasticity therapy)

Dietary Management

Protein restriction is the cornerstone of standard of care:

Age Group Protein Prescription
0–6 months ~2.0 g/kg/day
7–12 months ~1.6 g/kg/day
1–10 years ~1.3 g/kg/day
11–16 years ~0.9 g/kg/day
>16 years ~0.8 g/kg/day (range 0.4–1.2 g/kg/day)

Essential amino acid (EAA) supplements are prescribed for 74% of ARG1-D patients in European practice—the highest rate among all UCDs (PMID: 24113687).

Unique to ARG1-D: Unlike all other UCDs, arginine supplementation is contraindicated (as arginine is the accumulating substrate). "Most patients, except those with arginase deficiency, will need supplements of arginine" (PMID: 11148548).

MAXO terms: MAXO:0000087 (low-protein diet), MAXO:0000088 (amino acid supplementation)

Advanced Therapeutics

Gene Therapy (Preclinical)

AAV-based gene therapy has shown remarkable results in murine models: - Neonatal AAV administration rescues lethality in ARG1 knockout mice - Only minimal levels of hepatic arginase activity (~3.3% of normal) are sufficient for survival and functional ureagenesis (PMID: 25474440) - Gene therapy rescues cortical circuit abnormalities including dendritic complexity, synapse numbers, and intrinsic excitability (PMID: 27335400)

Hepatocyte Transplantation (Preclinical)

Human hepatocyte transplantation has been demonstrated to correct the metabolic defect in a murine model, providing proof of concept for cell-based therapy (PMID: 29724658).

CRISPR/Cas9 Gene Editing (Preclinical)

A CRISPR/Cas9-based strategy has been developed to restore arginase activity in patient-specific iPSC-derived hepatocytes, demonstrating restored ureagenesis in vitro (PMID: 27898091).

Surgical and Interventional

Liver Transplantation

  • Considered for metabolically unstable patients refractory to medical therapy
  • Provides a metabolic cure for the urea cycle defect
  • Does not reverse established neurological damage
  • A case of liver transplant for progressive biliary cirrhosis in ARG1-D has been reported (PMID: 21229317)
  • MAXO term: MAXO:0001175 (liver transplantation)

Supportive and Rehabilitative Care

Intervention MAXO Term Details
Physical therapy MAXO:0000502 For spasticity management and mobility
Occupational therapy MAXO:0000503 For ADL support
Speech therapy MAXO:0000930 For speech/language deficits (54% of patients)
Emergency protocol — Sick-day management with glucose infusion, protein cessation
Nutritional monitoring MAXO:0000087 Regular amino acid monitoring

Treatment Strategy

Standard of Care Algorithm: 1. First-line: Dietary protein restriction + essential amino acid supplements 2. Add-on: Nitrogen scavengers (sodium benzoate, phenylbutyrate) 3. Disease-modifying: Pegzilarginase (enzyme replacement) 4. Symptomatic: Antiepileptics (avoid valproate), antispasticity agents, rehabilitation 5. Refractory cases: Liver transplantation 6. Emergency: IV glucose, protein cessation, ammonia scavengers during metabolic crises

13. Prevention

Primary Prevention

  • Genetic counseling: Essential for at-risk families (carrier parents have 25% recurrence risk)
  • Carrier testing: Molecular testing of ARG1 for family members of affected individuals
  • Prenatal diagnosis: Available via CVS or amniocentesis with molecular genetic testing
  • Preimplantation genetic testing (PGT): Available for families with known pathogenic variants
  • MAXO terms: MAXO:0000079 (genetic counseling), MAXO:0000502 (prenatal diagnosis)

Secondary Prevention (Early Detection)

  • Newborn screening: Elevated arginine on dried blood spots via MS/MS; secondary target on U.S. RUSP; implemented in some European countries and in Portugal since 2007 (PMID: 38584907)
  • Improved screening algorithms: Use of arginine/ornithine ratio improves specificity (PMID: 28659245)
  • Targeted NBS: Recommended in regions with founder variants (e.g., Mayotte/Comoros) (PMID: 41684183)
  • Cascade screening: Family members of affected individuals

Tertiary Prevention

  • Strict adherence to protein-restricted diet
  • Regular biochemical monitoring (plasma arginine, ammonia)
  • Prompt treatment of intercurrent illness to prevent metabolic crises
  • Avoidance of valproate
  • Pegzilarginase to reduce arginine burden and prevent disease progression

14. Other Species / Natural Disease

Taxonomy

Arginase is highly conserved across species. ARG1 orthologs have been identified in:

Species NCBI Taxon ID Gene NCBI Gene ID
Mus musculus (mouse) 10090 Arg1 11846
Rattus norvegicus (rat) 10116 Arg1 29215
Danio rerio (zebrafish) 7955 arg1 —
Leishmania mexicana 5665 LmARG —
Schistosoma mansoni 6183 SmARG —
Trypanosoma cruzi 5693 TcFIGase (related) —

Natural Disease

No naturally occurring arginase 1 deficiency has been reported in companion animals or livestock. The disease is known only in humans and engineered animal models.

Comparative Biology

Arginase from parasitic organisms (Leishmania, Schistosoma) is a drug target because it initiates polyamine biosynthesis essential for parasite survival. Structural comparisons between human and parasitic arginases reveal that "residues important for substrate binding and catalysis are strictly conserved" despite only 42% sequence identity (PMID: 25007099). This evolutionary conservation underscores the fundamental importance of arginase in nitrogen metabolism across species.

15. Model Organisms

Mouse Models

Constitutive Knockout (Arg1^-/-)

  • Type: Complete germline knockout
  • Phenotype: Lethal by postnatal day 17 with severe hyperargininemia and hyperammonemia; weight loss begins ~day 15, gait instability, tail tremor, seizure-like activity (PMID: 25474440)
  • Limitations: Much more severe than typical human disease (neonatal lethality vs. childhood onset)

Conditional Adult Knockout (Arg1^fl/fl; CreERT2)

  • Tamoxifen-inducible global Arg1 deletion in adults
  • 100% of females and 70% of males died ~21 days after tamoxifen administration
  • Demonstrates that "the phenotypic abnormalities seen in the juvenile-onset model are not exclusive to the age of the animal but instead to the biochemistry of the disorder" (PMID: 23920045)

Liver-Specific Knockout (Arg1^fl/fl; AAV-TBG-Cre)

  • Liver-specific deletion recapitulates the full phenotype, confirming hepatic arginase as the critical isoform (PMID: 27761413)

Therapeutic Studies in Mouse Models

Therapy Model Outcome PMID
AAV gene therapy (neonatal) Arg1^-/- Long-term survival; only 3.3% enzyme activity needed 25474440
AAV gene therapy (cortical) Arg1^-/- Rescued cortical circuit defects 27335400
Human hepatocyte transplant Arg1^-/-/FAH^-/- Metabolic correction 29724658
CRISPR/Cas9 in iPSCs In vitro Restored ureagenesis in hepatocyte-like cells 27898091

Model Characteristics Summary

Phenotype recapitulation: - Mouse models faithfully reproduce hyperargininemia, hyperammonemia, neurological dysfunction, and lethality - The constitutive knockout is more severe than typical human disease - The conditional adult model better reflects the biochemistry of human disease

Limitations: - Neonatal lethality in the constitutive knockout limits long-term studies - The spastic diplegia characteristic of human disease is not well-modeled in mice - Seizure phenotype differs between species

Key insight from gene therapy studies: "only minimal levels of hepatic arginase activity are necessary for survival and ureagenesis in arginase-deficient mice" (PMID: 25474440) — suggesting that even partial enzyme restoration may be therapeutic in humans.

Key Findings Summary

F1: ARG1-D Is the Rarest UCD with Unique Pathophysiology

ARG1-D stands apart from other urea cycle disorders in that hyperargininemia—not hyperammonemia—is the primary disease driver. With a prevalence of ~1 in 1,000,000, it is ultra-rare. The 183 pathogenic/likely pathogenic variants in ClinVar span the entire ARG1 gene, with no clear genotype-phenotype correlation (PMID: 36049366; PMID: 26467175).

F2: Progressive Neurological Phenotype Distinguishes ARG1-D

The phenotype—progressive spasticity (69%), intellectual disability (64%), seizures (38%)—mimics cerebral palsy and hereditary spastic paraplegia, leading to diagnostic delays averaging 4+ years. The mean age at diagnosis of 6.4 years represents a critical gap in which irreversible neurological damage accumulates (PMID: 41651652; PMID: 35822089).

F3: ARG1 Protein Structure Determines Mutation Impact

The homotrimeric manganese metalloenzyme has three categories of functional disruption—active site, fold stability, and quaternary structure—explaining the diversity of pathogenic variants (PMID: 22959135).

F4: Pegzilarginase Transforms the Treatment Landscape

As the first approved disease-modifying therapy, pegzilarginase reduces plasma arginine by ~75% and improves motor function in 95% of patients. This represents a paradigm shift from purely supportive care to targeted metabolic correction (PMID: 38292042; PMID: 40714964).

F5: Early Diagnosis Is Critical for Outcome

The contrast between NBS-identified infants with early treatment (normal development) and late-diagnosed patients (severe disability) underscores the urgency of expanding newborn screening. Improved algorithms using arginine/ornithine ratios can achieve <0.01% recall rates while maintaining sensitivity (PMID: 28659245; PMID: 21229317).

Evidence Base

Key Literature

PMID Title Contribution
41651652 Clinical Characteristics of ARG1-D: Natural History from Clinical Trials Largest prospective cohort (n=48); definitive phenotype frequencies
36049366 Epidemiology, Diagnosis, and Management of ARG1-D: Systematic Review Prevalence data from 10 population studies
35236361 ARG1-D: Using Genetic Databases for Global Prevalence gnomAD-derived global birth prevalence estimates
35822089 Natural History of ARG1-D: Systematic Review of Case Reports 157-patient natural history; mean age at diagnosis
36175366 Role and Control of Arginine Levels in ARG1-D Hyperargininemia as primary driver; mechanism review
38292042 Pegzilarginase in ARG1-D (PEACE): Phase 3 Trial Pivotal efficacy data for enzyme replacement
40714964 Long-Term Pegzilarginase: Open-Label Extension Studies Sustained motor function improvements over 5 years
26467175 Arginase-1 Deficiency (Review) Comprehensive review of mutation spectrum and pathophysiology
22959135 Analysis of Novel ARG1 Mutations Structural mechanisms of missense mutation pathogenicity
28659245 Newborn Screening for Hyperargininemia Screening algorithm optimization
25474440 Minimal Ureagenesis for Survival in AAV-Treated Mice Only 3.3% enzyme activity needed for survival
27335400 Rescue of Motor Cortical Circuits by Gene Therapy Neuronal basis of motor dysfunction and reversibility
41684183 Cluster of Severe ARG1-D in the Comoros Founder effect and regional epidemiology
40237972 ARG1-D: A Treatable Form of Spastic Paraplegia Differential diagnosis and clinical recognition

Limitations and Knowledge Gaps

  1. Genotype-phenotype correlation: Despite >180 known pathogenic variants, no clear genotype-phenotype correlation exists. The contribution of modifier genes, epigenetic factors, and residual enzyme activity to phenotypic variability remains undefined.

  2. Neurotoxicity mechanisms: The precise molecular mechanisms by which hyperargininemia causes progressive neurological damage are incompletely understood. The relative contributions of arginine itself, guanidino compounds, nitric oxide pathway dysregulation, and ornithine deficiency require further elucidation.

  3. Long-term pegzilarginase outcomes: While up to 5-year data are encouraging, the long-term (decade+) effects on neurological progression, cognition, and quality of life with enzyme replacement therapy remain to be determined.

  4. Newborn screening optimization: ARG1-D is only a secondary target on the U.S. RUSP, and screening is not universal globally. Many patients are born in settings without newborn screening, leading to diagnostic delays.

  5. Adult outcomes: Very limited data exist on the adult natural history, particularly for patients diagnosed and treated early. Long-term cohort studies are needed.

  6. Biomarker development: Beyond plasma arginine, validated biomarkers for disease progression, CNS involvement, and treatment response are lacking.

  7. Reversibility of neurological damage: Whether established neurological damage can be reversed (vs. merely stabilized) with pegzilarginase or future therapies remains unclear.

  8. Rare phenotypes: Neonatal-onset presentations, hepatic manifestations, and late adult diagnoses are poorly characterized due to the ultra-rare nature of the disease.

Proposed Follow-up Experiments/Actions

  1. Multi-center longitudinal natural history study: Establish a comprehensive registry to track long-term outcomes across the spectrum of ARG1-D severity, including genotype-phenotype analyses with sufficient statistical power.

  2. CSF biomarker studies: Measure arginine, guanidino compounds, and neurodegeneration markers (neurofilament light chain, GFAP) in CSF to develop CNS-specific biomarkers of disease activity and treatment response.

  3. Expanded newborn screening: Advocate for ARG1-D elevation from secondary to primary target on RUSP; implement arginine/ornithine ratio algorithms globally; initiate targeted NBS in founder-effect populations (Comoros, Bulgaria).

  4. Neurotoxicity mechanistic studies: Conduct in vitro and in vivo studies using patient-derived iPSC neurons to dissect the relative neurotoxicity of arginine vs. guanidino compounds and their receptor targets.

  5. Gene therapy clinical trials: Based on strong preclinical evidence that only 3.3% enzyme restoration is sufficient, advance AAV-based liver-directed gene therapy to clinical trials.

  6. Cognitive outcome assessment with pegzilarginase: Design prospective studies with validated neuropsychological instruments to assess cognitive benefits of long-term arginine reduction.

  7. Epigenomic profiling: Perform DNA methylation and histone modification studies in ARG1-D patient tissues to identify epigenetic signatures that may contribute to disease variability or be targetable.

  8. Pharmacogenomic studies: Investigate whether ARG1 genotype influences pegzilarginase efficacy, optimal dosing, or immunogenicity risk.

Ontology Summary

Key Ontology Terms for Disease Knowledge Base

Category Terms
Disease MONDO:0009033 (arginase deficiency)
Gene HGNC:663 (ARG1)
Phenotypes HP:0001258 (spastic paraplegia), HP:0001249 (intellectual disability), HP:0001250 (seizures), HP:0003645 (elevated plasma arginine), HP:0001270 (motor delay), HP:0001987 (hyperammonemia), HP:0002167 (neurological speech impairment), HP:0001510 (growth delay)
GO Biological Process GO:0000050 (urea cycle), GO:0006525 (arginine metabolic process), GO:0006527 (arginine catabolic process), GO:0007268 (chemical synaptic transmission)
GO Cellular Component GO:0005737 (cytoplasm), GO:0005739 (mitochondrion), GO:0045202 (synapse)
GO Molecular Function GO:0004053 (arginase activity), GO:0030145 (manganese ion binding)
Cell Types CL:0000182 (hepatocyte), CL:0000679 (glutamatergic neuron), CL:0000540 (neuron), CL:0000232 (erythrocyte), CL:0000128 (oligodendrocyte)
Anatomy UBERON:0000955 (brain), UBERON:0002107 (liver), UBERON:0002240 (spinal cord), UBERON:0001384 (motor cortex), UBERON:0002316 (white matter)
Chemicals CHEBI:16467 (L-arginine), CHEBI:15729 (L-ornithine), CHEBI:16199 (urea), CHEBI:16134 (ammonia), CHEBI:16344 (guanidinoacetate)
Treatments MAXO:0001298 (enzyme replacement therapy), MAXO:0000087 (low-protein diet), MAXO:0000127 (nitrogen scavenger therapy), MAXO:0001175 (liver transplantation), MAXO:0000079 (genetic counseling), MAXO:0000950 (anticonvulsant therapy)

Report compiled from systematic literature review of 50 publications, covering epidemiology, genetics, pathophysiology, clinical features, diagnostics, treatment, and model organisms for Arginase 1 Deficiency.